Saquinavir
| Title | Journal |
|---|---|
| Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats. | Chemico-biological interactions 20161125 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. | Environmental health perspectives 20150501 |
| Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems. | Biochimica et biophysica acta 20140101 |
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | Toxicological sciences : an official journal of the Society of Toxicology 20131201 |
| GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration. | Antimicrobial agents and chemotherapy 20131201 |
| A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | Toxicological sciences : an official journal of the Society of Toxicology 20131101 |
| Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance. | Chemistry & biology 20130919 |
| Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies. | Journal of medicinal chemistry 20130912 |
| Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease. | Bioorganic & medicinal chemistry 20130901 |
| GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro. | Antimicrobial agents and chemotherapy 20130501 |
| In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor. | The Journal of antimicrobial chemotherapy 20130101 |
| Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. | Retrovirology 20130101 |
| Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents. | Journal of medicinal chemistry 20121213 |
| Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors. | Proteins 20121201 |
| Role of FAP48 in HIV-associated lipodystrophy. | Journal of cellular biochemistry 20121101 |
| Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. | Antimicrobial agents and chemotherapy 20121101 |
| Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. | Molecular pharmacology 20121001 |
| Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes. | AIDS research and human retroviruses 20120901 |
| Stereoselective evasion of P-glycoprotein, cytochrome P450 3A, and hydrolases by peptide prodrug modification of saquinavir. | Journal of pharmaceutical sciences 20120901 |
| Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort. | Medecine et maladies infectieuses 20120901 |
| Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling. | Journal of medicinal chemistry 20120809 |
| Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization. | Journal of medicinal chemistry 20120809 |
| Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes. | Drug metabolism and disposition: the biological fate of chemicals 20120801 |
| Microemulsions for oral administration and their therapeutic applications. | Expert opinion on drug delivery 20120801 |
| Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. | Oncology reports 20120801 |
| Investigation on the stability of saquinavir loaded liposomes: implication on stealth, release characteristics and cytotoxicity. | International journal of pharmaceutics 20120715 |
| Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing. | Antimicrobial agents and chemotherapy 20120701 |
| Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans. | Canadian journal of microbiology 20120701 |
| Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. | Journal of medicinal chemistry 20120614 |
| The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601 |
| Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. | AIDS (London, England) 20120601 |
| Perspectives on addressing ionization matrix effects in LC-MS bioanalysis. | Bioanalysis 20120601 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity. | AIDS (London, England) 20120515 |
| HIV protease inhibitors to prevent progression of cervical intraepithelial neoplasia to cervical cancer: therapeutic opportunities and challenges. | AIDS (London, England) 20120515 |
| Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120501 |
| Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. | Biopharmaceutics & drug disposition 20120501 |
| HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. | Biochemistry 20120403 |
| Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants. | Journal of clinical pharmacology 20120401 |
| The invasion of tobacco mosaic virus RNA induces endoplasmic reticulum stress-related autophagy in HeLa cells. | Bioscience reports 20120401 |
| Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. | Pharmaceutical research 20120401 |
| Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401 |
| Resistance to TRAIL and how to surmount it. | Immunologic research 20120401 |
| Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1. | PLoS biology 20120401 |
| Nanotechnology and the treatment of HIV infection. | Viruses 20120401 |
| Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium. | Journal of natural products 20120323 |
| Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors. | Journal of medicinal chemistry 20120322 |
| Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. | Cell cycle (Georgetown, Tex.) 20120315 |
| Expression of P-glycoprotein and multidrug resistance-associated protein on human brain-microvascular endothelial cells with electromagnetic stimulation. | Colloids and surfaces. B, Biointerfaces 20120301 |
| Modulation of efflux proteins by electromagnetic field for delivering azidothymidine and saquinavir into the brain. | Colloids and surfaces. B, Biointerfaces 20120301 |
| In vitro anti-neuroblastoma activity of saquinavir and its association with imatinib. | Oncology reports 20120301 |
| Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors. | Protein science : a publication of the Protein Society 20120301 |
| Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. | PLoS computational biology 20120301 |
| Exploring the complexity of the HIV-1 fitness landscape. | PLoS genetics 20120301 |
| High sodium butyrate levels induce MDR1 activation in colorectal cells: Impact of 15-deoxy-Δ(12,14)-prostaglandin J(2) on the resistance to saquinavir. | Biochemical and biophysical research communications 20120224 |
| Rational approaches to improving selectivity in drug design. | Journal of medicinal chemistry 20120223 |
| Terminal interface conformations modulate dimer stability prior to amino terminal autoprocessing of HIV-1 protease. | Biochemistry 20120207 |
| Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. | Colloids and surfaces. B, Biointerfaces 20120201 |
| Interaction of calf thymus DNA with the antiviral drug Lamivudine. | DNA and cell biology 20120101 |
| Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20120101 |
| Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. | International journal of vascular medicine 20120101 |
| Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120101 |
| The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co-administered with bioadhesive polymers and an AT1002 antagonist, AT1001. | The Journal of pharmacy and pharmacology 20120101 |
| The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. | Experimental diabetes research 20120101 |
| Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. | PloS one 20120101 |
| Probing amphotericin B single channel activity by membrane dipole modifiers. | PloS one 20120101 |
| Special aspects of the treatment of HIV-2-infected patients. | Intervirology 20120101 |
| A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. | PloS one 20120101 |
| Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs. | In vivo (Athens, Greece) 20120101 |
| Self-microemulsifying drug-delivery system for improved oral bioavailability of probucol: preparation and evaluation. | International journal of nanomedicine 20120101 |
| Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. | International journal of nanomedicine 20120101 |
| Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. | PloS one 20120101 |
| Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. | Clinical Medicine Insights. Cardiology 20120101 |
| Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. | BMC gastroenterology 20120101 |
| Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles. | PloS one 20120101 |
| HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. | PloS one 20120101 |
| Therapeutic potential of HIV protease-activable CASP3. | Scientific reports 20120101 |
| HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. | International journal of hepatology 20120101 |
| The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. | PloS one 20120101 |
| Ethanol-mediated regulation of cytochrome P450 2A6 expression in monocytes: role of oxidative stress-mediated PKC/MEK/Nrf2 pathway. | PloS one 20120101 |
| Stereoselective regulations of P-glycoprotein by ginsenoside Rh2 epimers and the potential mechanisms from the view of pharmacokinetics. | PloS one 20120101 |
| Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial. | AIDS research and treatment 20120101 |
| Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment. | Clinical & developmental immunology 20120101 |
| An overview of the evidence and mechanisms of herb-drug interactions. | Frontiers in pharmacology 20120101 |
| Failure to Control Caries in an AIDS-Affected Individual: A Case Report. | Case reports in dentistry 20120101 |
| Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. | PloS one 20120101 |
| Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008. | AIDS research and treatment 20120101 |
| Human immunodeficiency virus and leprosy coinfection: challenges in resource-limited setups. | Case reports in medicine 20120101 |
| Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile. | PloS one 20120101 |
| Receptor-independent interaction of bacterial lipopolysaccharide with lipid and lymphocyte membranes; the role of cholesterol. | PloS one 20120101 |
| Malaria and hiv in adults: when the parasite runs into the virus. | Mediterranean journal of hematology and infectious diseases 20120101 |
| Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study. | PloS one 20120101 |
| Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. | Alcoholism, clinical and experimental research 20111201 |
| Expression of ornithine decarboxylase during the transport of saquinavir across the blood-brain barrier using composite polymeric nanocarriers under an electromagnetic field. | Colloids and surfaces. B, Biointerfaces 20111201 |
| Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. | Colloids and surfaces. B, Biointerfaces 20111201 |
| Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. | Therapeutic drug monitoring 20111201 |
| Qualitative prediction of blood-brain barrier permeability on a large and refined dataset. | Journal of computer-aided molecular design 20111201 |
| Protease inhibitor-associated QT interval prolongation. | The Annals of pharmacotherapy 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. | PLoS pathogens 20111201 |
| Factors predicting the efficacy of adefovir dipivoxil on treatment-naïve chronic hepatitis B patients at 48 weeks. | Gut and liver 20111201 |
| Diagnosis & treatment of tuberculosis in HIV co-infected patients. | The Indian journal of medical research 20111201 |
| Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111120 |
| How much do antiretroviral drugs penetrate into the central nervous system? | Journal of medicine and life 20111114 |
| Polyethyleneimine/poly-(γ-glutamic acid)/poly(lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug. | Colloids and surfaces. B, Biointerfaces 20111101 |
| Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. | HIV medicine 20111101 |
| Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis. | Antiviral research 20111101 |
| In vitro activity of antiretroviral drugs against Plasmodium falciparum. | Antimicrobial agents and chemotherapy 20111101 |
| Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents. | Clinical pharmacokinetics 20111101 |
| Synthesis and antimalarial activity of thioetherhydroxyethylsulfonamides, potential aspartyl protease inhibitors, Part 3. | European journal of medicinal chemistry 20111101 |
| Evolution of a species-specific determinant within human CRM1 that regulates the post-transcriptional phases of HIV-1 replication. | PLoS pathogens 20111101 |
| Evaluation of metabolism-mediated herb-drug interactions. | Archives of pharmacal research 20111101 |
| In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats. | Basic & clinical pharmacology & toxicology 20111001 |
| Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. | Drug metabolism and disposition: the biological fate of chemicals 20111001 |
| Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. | Therapeutic drug monitoring 20111001 |
| [Vitamin D and drugs]. | Medizinische Monatsschrift fur Pharmazeuten 20111001 |
| Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid). | International journal of pharmaceutics 20110915 |
| Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier. | Journal of pharmaceutical sciences 20110901 |
| Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. | Drug metabolism and disposition: the biological fate of chemicals 20110901 |
| The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. | Antiviral research 20110901 |
| Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure. | Journal of medicinal chemistry 20110825 |
| HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step. | Virology 20110815 |
| Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: a case study with saquinavir. | Antiviral research 20110801 |
| Activation of HIV transcription by the viral Tat protein requires a demethylation step mediated by lysine-specific demethylase 1 (LSD1/KDM1). | PLoS pathogens 20110801 |
| Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir. | International journal of pharmaceutics 20110729 |
| Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells. | Journal of cellular physiology 20110701 |
| The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. | Antimicrobial agents and chemotherapy 20110601 |
| Predicting binding to p-glycoprotein by flexible receptor docking. | PLoS computational biology 20110601 |
| The influence of high-dose simvastatin and diltiazem on myocardium in rabbits: a haemodynamic study. | Archives of medical science : AMS 20110601 |
| The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts. | Biochemistry 20110531 |
| Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. | HIV medicine 20110501 |
| [Characteristics of antiretroviral drugs]. | Enfermedades infecciosas y microbiologia clinica 20110501 |
| CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. | PLoS pathogens 20110501 |
| Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. | PLoS pathogens 20110501 |
| Proper laboratory notebook practices: protecting your intellectual property. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401 |
| Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. | Antimicrobial agents and chemotherapy 20110401 |
| Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. | Clinical pharmacokinetics 20110401 |
| The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. | Therapeutic drug monitoring 20110401 |
| Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. | PLoS computational biology 20110401 |
| A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. | Journal of pharmaceutical and biomedical analysis 20110325 |
| Marginal increase of sunitinib exposure by grapefruit juice. | Cancer chemotherapy and pharmacology 20110301 |
| In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete. | Toxicology in vitro : an international journal published in association with BIBRA 20110301 |
| Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. | Drug metabolism and disposition: the biological fate of chemicals 20110301 |
| A Janus molecule provides a rational reshape to a multi-functional drug. | Cell cycle (Georgetown, Tex.) 20110301 |
| The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors. | Memorias do Instituto Oswaldo Cruz 20110301 |
| A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model. | Drug metabolism and disposition: the biological fate of chemicals 20110201 |
| The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. | Journal of pharmacokinetics and pharmacodynamics 20110201 |
| Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. | Journal of acquired immune deficiency syndromes (1999) 20110201 |
| In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. | Cell cycle (Georgetown, Tex.) 20110201 |
| Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. | PLoS pathogens 20110201 |
| Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. | PLoS pathogens 20110201 |
| Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children. | AIDS (London, England) 20110128 |
| Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation. | Journal of medicinal chemistry 20110127 |
| [Pharmacovigilance update]. | Revue medicale suisse 20110112 |
| Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. | International journal of cancer 20110101 |
| Determination of the antiretroviral drug nevirapine in diluted alkaline electrolyte by adsorptive stripping voltammetry at the mercury film electrode. | Combinatorial chemistry & high throughput screening 20110101 |
| The anti-tumor effects of human immunodeficiency virus protease inhibitors: ready for real time? | International journal of cancer 20110101 |
| Transwell-grown HepG2 cell monolayers as in vitro permeability model to study drug-drug or drug-food interactions. | Journal of medicinal food 20110101 |
| The HIV type 1 protease L10I minor mutation decreases replication capacity and confers resistance to protease inhibitors. | AIDS research and human retroviruses 20110101 |
| Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). | Molecular neurodegeneration 20110101 |
| Understanding diabetes in patients with HIV/AIDS. | Diabetology & metabolic syndrome 20110101 |
| Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101 |
| The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? | AIDS research and therapy 20110101 |
| Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. | Journal of medical case reports 20110101 |
| Penicillium marneffei Infection in AIDS. | Pathology research international 20110101 |
| Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. | AIDS research and therapy 20110101 |
| Time for gender mainstreaming in editorial policies. | Journal of the International AIDS Society 20110101 |
| 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice. | PloS one 20110101 |
| Genome-wide analysis of primary CD4+ and CD8+ T cell transcriptomes shows evidence for a network of enriched pathways associated with HIV disease. | Retrovirology 20110101 |
| Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series. | Radiation oncology (London, England) 20110101 |
| Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. | PloS one 20110101 |
| High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. | Journal of the International AIDS Society 20110101 |
| Machine learning on normalized protein sequences. | BMC research notes 20110101 |
| Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. | European journal of medical research 20110101 |
| Saquinavir: prolongation of PR and QT intervals. | Prescrire international 20110101 |
| The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. | European journal of medical research 20110101 |
| Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. | AIDS research and treatment 20110101 |
| Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer. | Breast cancer : basic and clinical research 20110101 |
| Strength of hydrogen bond network takes crucial roles in the dissociation process of inhibitors from the HIV-1 protease binding pocket. | PloS one 20110101 |
| The aspartic proteinase family of three Phytophthora species. | BMC genomics 20110101 |
| Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. | Malaria journal 20110101 |
| Safety and tolerability of antiretrovirals during pregnancy. | Infectious diseases in obstetrics and gynecology 20110101 |
| HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. | The open medicinal chemistry journal 20110101 |
| Contraception in HIV-positive female adolescents. | AIDS research and therapy 20110101 |
| A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial. | The open AIDS journal 20110101 |
| HIV and HAART-Associated Dyslipidemia. | The open cardiovascular medicine journal 20110101 |
| Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20110101 |
| The preparation of 3,5-dihydroxy-4-isopropylstilbene nanoemulsion and in vitro release. | International journal of nanomedicine 20110101 |
| Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. | PloS one 20110101 |
| Novel natural inhibitors of CYP1A2 identified by in silico and in vitro screening. | International journal of molecular sciences 20110101 |
| Tolvaptan, hyponatremia, and heart failure. | International journal of nephrology and renovascular disease 20110101 |
| Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice. | International journal of nanomedicine 20110101 |
| Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. | Journal of microencapsulation 20110101 |
| Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. | PloS one 20110101 |
| Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer. | International journal of nanomedicine 20110101 |
| Clinical therapeutics in pregnancy. | Journal of biomedicine & biotechnology 20110101 |
| Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. | PloS one 20110101 |
| Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. | PloS one 20110101 |
| [Evidence-based therapeutic drug monitoring for saquinavir]. | Therapie 20110101 |
| Buyer beware? Does the information provided with herbal products available over the counter enable safe use? | BMC medicine 20110101 |
| Recent developments of peptidomimetic HIV-1 protease inhibitors. | Current medicinal chemistry 20110101 |
| HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. | Retrovirology 20110101 |
| HIV-Associated Venous Thromboembolism. | Mediterranean journal of hematology and infectious diseases 20110101 |
| HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. | PloS one 20110101 |
| Clinical herbal interactions with conventional drugs: from molecules to maladies. | Current medicinal chemistry 20110101 |
| Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review. | Journal of medical case reports 20110101 |
| A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. | PloS one 20110101 |
| Bioequivalence study of two oral tablet formulations containing saquinavir mesylate boosted with ritonavir in healthy male subjects. | Arzneimittel-Forschung 20110101 |
| Primary cutaneous B-cell lymphoma successfully treated with highly active antiretroviral therapy alone: a case report and review of the literature. | Indian journal of dermatology 20110101 |
| Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system. | Journal of pharmacy & bioallied sciences 20110101 |
| Meet me on the other side: trans-bilayer modulation of a model voltage-gated ion channel activity by membrane electrostatics asymmetry. | PloS one 20110101 |
| Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. | PloS one 20110101 |
| Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus. | Journal of pharmacology & pharmacotherapeutics 20110101 |
| South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. | Indian journal of endocrinology and metabolism 20110101 |
| Human immunodeficiency virus endocrinopathy. | Indian journal of endocrinology and metabolism 20110101 |
| Choosing a gliptin. | Indian journal of endocrinology and metabolism 20110101 |
| In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate. | International journal of nanomedicine 20110101 |
| Drugs for malaria: something old, something new, something borrowed. | F1000 biology reports 20110101 |
| Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. | PloS one 20110101 |
| Wild-type Drosophila melanogaster as a model host to analyze nitrogen source dependent virulence of Candida albicans. | PloS one 20110101 |
| AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. | BMC research notes 20110101 |
| Elevated pressure downregulates ZO-1 expression and disrupts cytoskeleton and focal adhesion in human trabecular meshwork cells. | Molecular vision 20110101 |
| Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. | Retrovirology 20110101 |
| Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. | Antiviral therapy 20110101 |
| Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients. | Antiviral therapy 20110101 |
| Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. | BMC infectious diseases 20110101 |
| A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. | BMC bioinformatics 20110101 |
| Mutations affecting interaction of integrase with TNPO3 do not prevent HIV-1 cDNA nuclear import. | Retrovirology 20110101 |
| Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. | BMC pulmonary medicine 20110101 |
| Nanomedicine as an emerging approach against intracellular pathogens. | International journal of nanomedicine 20110101 |
| Critical appraisal of ticagrelor in the management of acute coronary syndrome. | Therapeutics and clinical risk management 20110101 |
| Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. | International journal of nanomedicine 20110101 |
| Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. | Clinical pharmacology : advances and applications 20110101 |
| Multidrug resistance in breast cancer: from in vitro models to clinical studies. | International journal of breast cancer 20110101 |
| Evaluation of the use of partition coefficients and molecular surface properties as predictors of drug absorption: a provisional biopharmaceutical classification of the list of national essential medicines of Pakistan. | Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101 |
| Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma. | Indian journal of pharmaceutical sciences 20110101 |
| Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101223 |
| Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. | Experimental parasitology 20101201 |
| Comparative efflux of saquinavir, ritonavir and lopinavir from primary human cells. | Drug metabolism letters 20101201 |
| Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | Toxicological sciences : an official journal of the Society of Toxicology 20101201 |
| Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. | Drug metabolism and disposition: the biological fate of chemicals 20101201 |
| Nicotine and cotinine increases the brain penetration of saquinavir in rat. | Journal of neurochemistry 20101201 |
| Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. | Neoplasia (New York, N.Y.) 20101201 |
| HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes. | The Indian journal of medical research 20101201 |
| FDA notifications. New risk information added to label of antiviral saquinavir. | AIDS alert 20101201 |
| Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. | AIDS (London, England) 20101127 |
| Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101120 |
| HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces. | Mycoses 20101101 |
| Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. | Drug metabolism and disposition: the biological fate of chemicals 20101101 |
| Impact of drug transporters on cellular resistance towards saquinavir and darunavir. | The Journal of antimicrobial chemotherapy 20101101 |
| Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. | AIDS research and human retroviruses 20101101 |
| Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. | Advances in therapy 20101101 |
| HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy. | Biopharmaceutics & drug disposition 20101101 |
| Molecular Basis for Drug Resistance in HIV-1 Protease. | Viruses 20101101 |
| Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity. | Journal of neurochemistry 20101001 |
| Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. | Journal of Korean medical science 20101001 |
| HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. | Journal of pharmaceutical and biomedical analysis 20100905 |
| Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. | European journal of obstetrics, gynecology, and reproductive biology 20100901 |
| Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. | Analytical and bioanalytical chemistry 20100901 |
| Saquinavir/ritonavir monotherapy as a new nucleoside-sparing maintenance strategy in long-term virologically suppressed HIV-infected patients. | Current HIV research 20100901 |
| Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. | The FEBS journal 20100901 |
| Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. | Antimicrobial agents and chemotherapy 20100801 |
| A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. | Clinical chemistry and laboratory medicine 20100801 |
| Methadone, buprenorphine, and street drug interactions with antiretroviral medications. | Current HIV/AIDS reports 20100801 |
| Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. | Archives of internal medicine 20100726 |
| Impact of hyperlipidemia on plasma protein binding and hepatic drug transporter and metabolic enzyme regulation in a rat model of gestational diabetes. | The Journal of pharmacology and experimental therapeutics 20100701 |
| Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. | Drug metabolism and disposition: the biological fate of chemicals 20100701 |
| Enhancing the delivery of anti retroviral drug 'Saquinavir' across the blood brain barrier using nanoparticles. | Current HIV research 20100701 |
| Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. | The Journal of infectious diseases 20100701 |
| Effect of electromagnetic field on endocytosis of cationic solid lipid nanoparticles by human brain-microvascular endothelial cells. | Journal of drug targeting 20100701 |
| Role of Gag in HIV Resistance to Protease Inhibitors. | Viruses 20100701 |
| Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. | AIDS (London, England) 20100619 |
| Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex. | Biochemical and biophysical research communications 20100611 |
| Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601 |
| Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. | British journal of clinical pharmacology 20100601 |
| Overcoming multidrug resistance in human cancer cells by natural compounds. | Toxins 20100601 |
| Accurate ensemble molecular dynamics binding free energy ranking of multidrug-resistant HIV-1 proteases. | Journal of chemical information and modeling 20100524 |
| Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. | The Journal of antimicrobial chemotherapy 20100501 |
| Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. | Journal of virology 20100501 |
| Special issue: retroviral enzymes. | Viruses 20100501 |
| Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir). | Journal of clinical pharmacology 20100401 |
| Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients. | Infection 20100401 |
| Arrhythmia risk with saquinavir. | AIDS patient care and STDs 20100401 |
| Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. | The new microbiologica 20100401 |
| FDA notifications. Potential serious effect of combination saquinavir-ritonavir. | AIDS alert 20100401 |
| A dynamic model of HIV integrase inhibition and drug resistance. | Journal of molecular biology 20100326 |
| Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. | Xenobiotica; the fate of foreign compounds in biological systems 20100301 |
| Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. | International journal of clinical pharmacology and therapeutics 20100301 |
| Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. | Biopharmaceutics & drug disposition 20100301 |
| Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases. | Journal of medicinal chemistry 20100225 |
| Mechanistic insight from in silico pharmacokinetic experiments: roles of P-glycoprotein, Cyp3A4 enzymes, and microenvironments. | The Journal of pharmacology and experimental therapeutics 20100201 |
| HIV protease inhibitors block oral epithelial cell DNA synthesis. | Archives of oral biology 20100201 |
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. | The Journal of infectious diseases 20100201 |
| [The newest developments in anti-HIV-1 drugs]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100201 |
| HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells. | Journal of medicinal chemistry 20100128 |
| Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. | Journal of pharmaceutical sciences 20100101 |
| Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. | Journal of acquired immune deficiency syndromes (1999) 20100101 |
| Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. | Current topics in medicinal chemistry 20100101 |
| Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS. | Journal of molecular graphics & modelling 20100101 |
| The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes. | British journal of pharmacology 20100101 |
| Pooling ARV Drug Patents: A Pro-Access Fitting Strategy? | The open AIDS journal 20100101 |
| Profile of etravirine for the treatment of HIV infection. | Therapeutics and clinical risk management 20100101 |
| Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. | Particle and fibre toxicology 20100101 |
| Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics. | The open AIDS journal 20100101 |
| Successful treatment of HIV-associated multicentric Castleman's disease and multiple organ failure with rituximab and supportive care: a case report. | Journal of medical case reports 20100101 |
| Technology Development Through Pooling ARV Drug Patents: A Vision from China. | The open AIDS journal 20100101 |
| Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. | Retrovirology 20100101 |
| Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. | AIDS research and therapy 20100101 |
| Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. | PloS one 20100101 |
| The protease inhibitors ritonavir and saquinavir influence lipid metabolism: a pig model for the rapid evaluation of new drugs. | Antiviral therapy 20100101 |
| Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs. | Marine drugs 20100101 |
| Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. | Current chemical genomics 20100101 |
| Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. | European journal of medical research 20100101 |
| Semen may harbor HIV despite effective HAART: another piece in the puzzle. | PloS one 20100101 |
| Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. | PloS one 20100101 |
| An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells. | PloS one 20100101 |
| Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. | PloS one 20100101 |
| A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. | PloS one 20100101 |
| Immunomodulation in female B₆C₃F₁ mice following treatment with the HIV protease inhibitor saquinavir for 28 days by gavage. | Journal of immunotoxicology 20100101 |
| Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications? | European journal of medical research 20100101 |
| Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. | AIDS research and therapy 20100101 |
| The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. | Drug metabolism and pharmacokinetics 20100101 |
| Development of a liposomal nanodelivery system for nevirapine. | Journal of biomedical science 20100101 |
| Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. | PloS one 20100101 |
| Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. | Neuropsychiatric disease and treatment 20100101 |
| Severe leukoencephalopathy with fulminant cerebral edema reflecting immune reconstitution inflammatory syndrome during HIV infection: a case report. | Journal of medical case reports 20100101 |
| Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study. | AIDS research and therapy 20100101 |
| Stevens-Johnson syndrome associated with nevirapine use in an HIV-positive pregnant woman: a case report. | West African journal of medicine 20100101 |
| Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. | PloS one 20100101 |
| Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice. | BMC gastroenterology 20100101 |
| Specific eradication of HIV-1 from infected cultured cells. | AIDS research and therapy 20100101 |
| Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. | Retrovirology 20100101 |
| Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. | PloS one 20100101 |
| Assessing the performance of a computer-based policy model of HIV and AIDS. | PloS one 20100101 |
| Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. | PloS one 20100101 |
| Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. | Clinical epidemiology 20100101 |
| Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. | Drug metabolism and pharmacokinetics 20100101 |
| Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. | Scientia pharmaceutica 20100101 |
| The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. | BMC pediatrics 20100101 |
| Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. | European journal of medical research 20100101 |
| Progress in antiretroviral drug delivery using nanotechnology. | International journal of nanomedicine 20100101 |
| The interaction of N-acylhomoserine lactone quorum sensing signaling molecules with biological membranes: implications for inter-kingdom signaling. | PloS one 20100101 |
| Routine HIV screening in France: clinical impact and cost-effectiveness. | PloS one 20100101 |
| Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. | Core evidence 20100101 |
| Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. | PloS one 20100101 |
| In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. | Antiviral therapy 20100101 |
| Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution. | AIDS research and therapy 20100101 |
| Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. | BMC infectious diseases 20100101 |
| Interchangeability of two 500 mg amoxicillin capsules with one 1000 mg amoxicillin tablet after a single oral administration. | Indian journal of pharmaceutical sciences 20100101 |
| Saxagliptin for type 2 diabetes. | Diabetes, metabolic syndrome and obesity : targets and therapy 20100101 |
| Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients. | AIDS research and treatment 20100101 |
| Tuberculosis of spine. | Journal of craniovertebral junction & spine 20100101 |
| Pharmacogenetics in the brazilian population. | Frontiers in pharmacology 20100101 |
| Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Long-term treatment of patients with HIV-1: the role of atazanavir. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. | Journal of blood medicine 20100101 |
| Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance. | Journal of medicinal chemistry 20091210 |
| Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. | The Journal of antimicrobial chemotherapy 20091201 |
| Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. | Therapeutic drug monitoring 20091201 |
| Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. | Biological & pharmaceutical bulletin 20091201 |
| Drug repositioning using in silico compound profiling. | Future medicinal chemistry 20091201 |
| HIV-1 Protease: Structural Perspectives on Drug Resistance. | Viruses 20091201 |
| Current and Novel Inhibitors of HIV Protease. | Viruses 20091201 |
| How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. | AIDS (London, England) 20091113 |
| Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies. | Journal of pharmaceutical sciences 20091101 |
| Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism. | Experimental parasitology 20091001 |
| A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. | Journal of medical virology 20091001 |
| A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001 |
| Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. | Bioorganic & medicinal chemistry 20091001 |
| Saquinavir, the pioneer antiretroviral protease inhibitor. | Expert opinion on drug metabolism & toxicology 20091001 |
| Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. | Pharmacotherapy 20091001 |
| The role of transporters in the pharmacokinetics of orally administered drugs. | Pharmaceutical research 20090901 |
| The history of antiretrovirals: key discoveries over the past 25 years. | Reviews in medical virology 20090901 |
| Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. | Journal of pharmaceutical sciences 20090801 |
| Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. | Medical microbiology and immunology 20090801 |
| The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placenta. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090712 |
| Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies. | Journal of medicinal chemistry 20090709 |
| Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. | Antimicrobial agents and chemotherapy 20090701 |
| Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy. | Addiction biology 20090701 |
| Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance. | Journal of chemical information and modeling 20090701 |
| Renal transplantation in a HIV positive patient. | Indian journal of nephrology 20090701 |
| Effectiveness of commercial inhibitors against subtype F HIV-1 protease. | Journal of enzyme inhibition and medicinal chemistry 20090601 |
| Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. | The Journal of antimicrobial chemotherapy 20090601 |
| Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. | AIDS (London, England) 20090601 |
| Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. | Proteins 20090515 |
| Proteolytic cleavage of HIV-1 GFP-Vpr fusions at novel sites within virions and living cells: concerns for intracellular trafficking studies. | Journal of fluorescence 20090501 |
| The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. | Antiviral research 20090501 |
| On-line desorption of dried blood spot: A novel approach for the direct LC/MS analysis of micro-whole blood samples. | Journal of pharmaceutical and biomedical analysis 20090501 |
| Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. | The Journal of antimicrobial chemotherapy 20090501 |
| The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. | Molecular cancer therapeutics 20090501 |
| Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease. | Journal of medicinal chemistry 20090423 |
| Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures. | Proteins 20090401 |
| Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. | International journal of antimicrobial agents 20090401 |
| Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. | Journal of acquired immune deficiency syndromes (1999) 20090401 |
| HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone. | Experimental biology and medicine (Maywood, N.J.) 20090401 |
| A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors. | Rapid communications in mass spectrometry : RCM 20090401 |
| Synthesis and antimalarial activity of hydroxyethylpiperazine derivatives. | European journal of medicinal chemistry 20090301 |
| GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. | Antimicrobial agents and chemotherapy 20090301 |
| Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G. | The Journal of antimicrobial chemotherapy 20090301 |
| The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells. | Gynecologic oncology 20090301 |
| Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. | PLoS pathogens 20090301 |
| Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215 |
| Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes. | Toxicology in vitro : an international journal published in association with BIBRA 20090201 |
| The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. | British journal of pharmacology 20090201 |
| Warfarin-antiretroviral interactions. | The Annals of pharmacotherapy 20090201 |
| Role of NEDD8 in HIV-associated lipodystrophy. | Differentiation; research in biological diversity 20090201 |
| Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. | International journal of pharmaceutics 20090105 |
| Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. | Drug metabolism and disposition: the biological fate of chemicals 20090101 |
| Contraception and HIV infection in women. | Human reproduction update 20090101 |
| Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. | Clinical chemistry 20090101 |
| HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. | The Journal of infectious diseases 20090101 |
| Anti-HIV drugs for cancer therapeutics: back to the future? | The Lancet. Oncology 20090101 |
| Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways. | PPAR research 20090101 |
| Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modeling: model structure and parameters determination. | Theoretical biology & medical modelling 20090101 |
| Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? | AIDS research and therapy 20090101 |
| Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors. | Retrovirology 20090101 |
| Darunavir: a review of its use in the management of HIV infection in adults. | Drugs 20090101 |
| HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. | PloS one 20090101 |
| Is PPARγ a prospective player in HIV-1-associated bone disease? | PPAR research 20090101 |
| Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. | Antiviral therapy 20090101 |
| Role of atazanavir in the treatment of HIV infection. | Therapeutics and clinical risk management 20090101 |
| The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. | Antiviral therapy 20090101 |
| Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. | PloS one 20090101 |
| Pregnancy outcomes among HIV-infected women undergoing antiretroviral therapy. | The open AIDS journal 20090101 |
| Preparation and performance evaluation of saquinavir laden cationic submicron emulsions. | Drug delivery 20090101 |
| Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. | PloS one 20090101 |
| Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. | PloS one 20090101 |
| The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study. | Interdisciplinary perspectives on infectious diseases 20090101 |
| Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. | Vascular health and risk management 20090101 |
| Pharmacotherapy of pediatric and adolescent HIV infection. | Therapeutics and clinical risk management 20090101 |
| Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. | Therapeutics and clinical risk management 20090101 |
| Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101 |
| Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease. | BMC bioinformatics 20090101 |
| Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. | PloS one 20090101 |
| Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. | Retrovirology 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Estradiol and progesterone-mediated regulation of P-gp in P-gp overexpressing cells (NCI-ADR-RES) and placental cells (JAR). | Molecular pharmaceutics 20090101 |
| Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. | BMC bioinformatics 20090101 |
| Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. | Journal of biomedicine & biotechnology 20090101 |
| RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. | AIDS research and therapy 20090101 |
| The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia. | The open virology journal 20090101 |
| Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. | PloS one 20090101 |
| Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques. | Retrovirology 20090101 |
| First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients--making a good thing better. | AIDS reviews 20090101 |
| German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. | European journal of medical research 20090101 |
| HIV- 1 protease inhibits Cap- and poly(A)-dependent translation upon eIF4GI and PABP cleavage. | PloS one 20090101 |
| Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. | Obstetrics and gynecology international 20090101 |
| Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. | BMC infectious diseases 20090101 |
| Hepatic profile analyses of tipranavir in Phase II and III clinical trials. | BMC infectious diseases 20090101 |
| Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients. | AIDS research and therapy 20090101 |
| Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. | AIDS research and therapy 20090101 |
| Disfiguring molluscum contagiosum in a HIV-positive patient responding to antiretroviral therapy. | Indian journal of dermatology 20090101 |
| A comprehensive review of immunosuppression used for liver transplantation. | Journal of transplantation 20090101 |
| Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy. | Infectious diseases in obstetrics and gynecology 20090101 |
| Role of multidrug transporters in neurotherapeutics. | Annals of Indian Academy of Neurology 20090101 |
| Raltegravir: The evidence of its therapeutic value in HIV-1 infection. | Core evidence 20090101 |
| Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma. | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20090101 |
| Profile of darunavir in the management of treatment-experienced HIV patients. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Role of darunavir in the management of HIV infection. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Limited-sampling strategies for anti-infective agents: systematic review. | The Canadian journal of hospital pharmacy 20090101 |
| Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. | Journal of pharmaceutical sciences 20081201 |
| A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells. | Biotechnology and bioengineering 20081201 |
| Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir. | European journal of clinical pharmacology 20081201 |
| A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. | Drug metabolism and disposition: the biological fate of chemicals 20081201 |
| Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. | The Journal of antimicrobial chemotherapy 20081201 |
| An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. | Therapeutic drug monitoring 20081201 |
| PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. | Journal of medical virology 20081201 |
| P-gp inhibition potential in cell-based models: which 'calculation' method is the most accurate? | The AAPS journal 20081201 |
| Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients. | Therapeutics and clinical risk management 20081201 |
| Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors. | The Journal of antimicrobial chemotherapy 20081101 |
| Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. | The Journal of infectious diseases 20081101 |
| Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. | Journal of acquired immune deficiency syndromes (1999) 20081101 |
| Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression. | Current HIV research 20081101 |
| Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. | British journal of pharmacology 20081101 |
| Clinical pharmacology of HIV protease inhibitors in pregnancy. | Current opinion in HIV and AIDS 20081101 |
| Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir. | Journal of medicinal chemistry 20081023 |
| Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies. | Journal of medicinal chemistry 20081009 |
| Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): evasion of MRP-2 mediated efflux. | International journal of pharmaceutics 20081001 |
| Maraviroc: in vitro assessment of drug-drug interaction potential. | British journal of clinical pharmacology 20081001 |
| [Chemical characteristics, mechanism of action and antiviral activity of darunavir]. | Enfermedades infecciosas y microbiologia clinica 20081001 |
| Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. | Therapeutics and clinical risk management 20081001 |
| Impedance method for detecting HIV-1 protease and screening for its inhibitors using ferrocene-peptide conjugate/Au nanoparticle/single-walled carbon nanotube modified electrode. | Analytical chemistry 20080915 |
| MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells. | Experimental biology and medicine (Maywood, N.J.) 20080901 |
| A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. | Antiviral research 20080901 |
| Ultra-fast quantitation of saquinavir in human plasma by matrix-assisted laser desorption/ionization and selected reaction monitoring mode detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901 |
| HIV infection in the elderly. | Clinical interventions in aging 20080901 |
| Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance. | Journal of medicinal chemistry 20080814 |
| Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. | Drug metabolism and disposition: the biological fate of chemicals 20080801 |
| Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. | British journal of clinical pharmacology 20080801 |
| Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir. | Journal of molecular biology 20080801 |
| Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. | Therapeutic drug monitoring 20080801 |
| Roche Labs update insert for saquinavir. | AIDS alert 20080801 |
| Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy. | Journal of Korean medical science 20080801 |
| Combating HIV resistance - focus on darunavir. | Therapeutics and clinical risk management 20080801 |
| Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors. | European journal of medicinal chemistry 20080701 |
| Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis. | The Journal of infection 20080701 |
| Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. | Drug metabolism and disposition: the biological fate of chemicals 20080701 |
| Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. | Drug metabolism and disposition: the biological fate of chemicals 20080701 |
| Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. | The Journal of antimicrobial chemotherapy 20080701 |
| Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. | The Pediatric infectious disease journal 20080701 |
| Quantitative analysis of antiretroviral drugs in lysates of peripheral blood mononuclear cells using MALDI-triple quadrupole mass spectrometry. | Analytical chemistry 20080701 |
| Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation. | Journal of acquired immune deficiency syndromes (1999) 20080701 |
| Invirase package insert updated. | AIDS patient care and STDs 20080701 |
| (S)-1,5-Dibenzyl-3-tert-butyl-imidazol-idin-4-one. | Acta crystallographica. Section E, Structure reports online 20080701 |
| Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). | Journal of medicinal chemistry 20080612 |
| Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. | British journal of cancer 20080603 |
| Quality control of protease inhibitors. | Journal of pharmaceutical sciences 20080601 |
| Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. | Clinical pharmacology and therapeutics 20080601 |
| Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. | The Journal of antimicrobial chemotherapy 20080601 |
| Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz. | AIDS research and human retroviruses 20080601 |
| Screening and Management of HIV-2-Infected Individuals in Northern Italy. | AIDS patient care and STDs 20080601 |
| In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. | The AAPS journal 20080601 |
| Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. | The AAPS journal 20080601 |
| Atriplatrade mark - HIV therapy in one pill. | Therapeutics and clinical risk management 20080601 |
| Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry. | Analytical chemistry 20080515 |
| An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat. | Pharmaceutical research 20080501 |
| Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats. | Drug metabolism and disposition: the biological fate of chemicals 20080501 |
| Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. | The Journal of antimicrobial chemotherapy 20080501 |
| Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. | Cancer biology & therapy 20080501 |
| Inhibitory quotient in HIV pharmacology. | Current opinion in HIV and AIDS 20080501 |
| Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. | Current opinion in HIV and AIDS 20080501 |
| Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. | Journal of computational chemistry 20080415 |
| Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). | Journal of acquired immune deficiency syndromes (1999) 20080401 |
| Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). | Drug metabolism and disposition: the biological fate of chemicals 20080401 |
| Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742. | Antimicrobial agents and chemotherapy 20080401 |
| Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. | Chemical biology & drug design 20080401 |
| Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil. | Journal of acquired immune deficiency syndromes (1999) 20080401 |
| Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. | British journal of clinical pharmacology 20080401 |
| Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. | British journal of clinical pharmacology 20080401 |
| Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. | International journal of pharmaceutics 20080303 |
| Natural and synthetic polymers as inhibitors of drug efflux pumps. | Pharmaceutical research 20080301 |
| Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. | Biopharmaceutics & drug disposition 20080301 |
| Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. | PLoS medicine 20080301 |
| Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases. | Journal of the American Chemical Society 20080227 |
| Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure. | Bioorganic & medicinal chemistry 20080201 |
| Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark). | Therapeutics and clinical risk management 20080201 |
| Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. | International journal of pharmaceutics 20080122 |
| Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir. | Bioorganic & medicinal chemistry 20080115 |
| The prevalence and risk of hepatitis flares in a Serbian cohort of HIV and HCV co-infected patients treated with HAART. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101 |
| Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. | The Journal of antimicrobial chemotherapy 20080101 |
| Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy. | Autophagy 20080101 |
| Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-beta-cyclodextrin formulations. | Biomacromolecules 20080101 |
| Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. | Journal of acquired immune deficiency syndromes (1999) 20080101 |
| Drug interactions between HIV protease inhibitors and acid-reducing agents. | Clinical pharmacokinetics 20080101 |
| Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. | Retrovirology 20080101 |
| The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. | Retrovirology 20080101 |
| Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. | BMC neuroscience 20080101 |
| Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. | Retrovirology 20080101 |
| Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy. | Retrovirology 20080101 |
| Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. | AIDS research and therapy 20080101 |
| Proteochemometric modeling of HIV protease susceptibility. | BMC bioinformatics 20080101 |
| Influence of adenosine triphosphate and ABCB1 (MDR1) genotype on the P-glycoprotein-dependent transfer of saquinavir in the dually perfused human placenta. | Human & experimental toxicology 20080101 |
| Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy. | Acta poloniae pharmaceutica 20080101 |
| Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. | Antiviral therapy 20080101 |
| P-glycoprotein expression in HTLV-III cells after treatment with HIV-1 protease inhibitors. | Ethnicity & disease 20080101 |
| beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL. | Retrovirology 20080101 |
| Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence. | PloS one 20080101 |
| Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. | BMC infectious diseases 20080101 |
| Double-boosted protease inhibitor antiretroviral regimens: what role? | Drugs 20080101 |
| 25 years of HIV-1 research - progress and perspectives. | BMC medicine 20080101 |
| Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report. | Journal of medical case reports 20080101 |
| CD8+ T-cell interleukin-7 receptor alpha expression as a potential indicator of disease status in HIV-infected children. | PloS one 20080101 |
| Mechanistic simulations explain paradoxical saquinavir metabolism during in vitro vectorial transport study. | Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20080101 |
| Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. | Antiviral therapy 20080101 |
| Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. | Bioinformation 20080101 |
| Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina. | Journal of the International AIDS Society 20080101 |
| Insights into a mutation-assisted lateral drug escape mechanism from the HIV-1 protease active site. | Biochemistry 20071225 |
| Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | The Journal of antimicrobial chemotherapy 20071201 |
| Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. | Therapeutic drug monitoring 20071201 |
| Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. | AIDS patient care and STDs 20071201 |
| HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115 |
| Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations. | Journal of molecular graphics & modelling 20071101 |
| Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition. | Clinical and vaccine immunology : CVI 20071101 |
| Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. | Basic & clinical pharmacology & toxicology 20071101 |
| Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. | HIV medicine 20071101 |
| Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. | PLoS medicine 20071101 |
| Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. | Clinical therapeutics 20071101 |
| The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. | Clinical pharmacology and therapeutics 20071001 |
| Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. | The Journal of antimicrobial chemotherapy 20071001 |
| Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. | The Journal of biological chemistry 20070928 |
| Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. | AIDS (London, England) 20070912 |
| Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres. | Journal of medicinal chemistry 20070906 |
| Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070901 |
| Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. | Canadian journal of physiology and pharmacology 20070901 |
| MDR1 polymorphisms effect cyclosporine AUC0-4 values in Behçet's disease patients. | Clinical ophthalmology (Auckland, N.Z.) 20070901 |
| Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals. | Immunology letters 20070815 |
| Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. | Clinical pharmacology and therapeutics 20070801 |
| Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. | International journal of pharmaceutics 20070801 |
| Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. | Antimicrobial agents and chemotherapy 20070801 |
| Clinical studies with oral lipid based formulations of poorly soluble compounds. | Therapeutics and clinical risk management 20070801 |
| Review of tipranavir in the treatment of drug-resistant HIV. | Therapeutics and clinical risk management 20070801 |
| Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. | AIDS (London, England) 20070731 |
| Development and validation of a reversed-phase liquid chromatographic method with fluorescence detection for the study of Saquinavir pharmacokinetics in rat plasma. | Analytica chimica acta 20070702 |
| Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. | The Journal of antimicrobial chemotherapy 20070701 |
| Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. | AIDS (London, England) 20070701 |
| Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070601 |
| Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir. | Hematological oncology 20070601 |
| A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. | Antimicrobial agents and chemotherapy 20070601 |
| HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA. | Biochemical pharmacology 20070601 |
| Clinical response and tolerability to and safety of saquinavir with low-dose ritonavir in human immunodeficiency virus type 1-infected mothers and their infants. | Antimicrobial agents and chemotherapy 20070601 |
| The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070601 |
| Therapeutic issues in HIV/HCV-coinfected patients. | Journal of viral hepatitis 20070601 |
| Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals. | Therapeutic drug monitoring 20070601 |
| Higher-order oligomerization targets plasma membrane proteins and HIV gag to exosomes. | PLoS biology 20070601 |
| Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats. | International journal of pharmaceutics 20070524 |
| HIV protease inhibitors enhance the efficacy of irradiation. | Cancer research 20070515 |
| Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. | Clinical pharmacology and therapeutics 20070501 |
| Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen. | The Journal of antimicrobial chemotherapy 20070501 |
| Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. | HIV medicine 20070501 |
| Multidrug resistance proteins affect drug transmission across the placenta. | American journal of obstetrics and gynecology 20070501 |
| Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells. | Mycoses 20070501 |
| Combining resistance and pharmacology for optimum patient care. | Current opinion in HIV and AIDS 20070501 |
| Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. | The Journal of infection 20070401 |
| Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070401 |
| An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. | Journal of pharmacokinetics and pharmacodynamics 20070401 |
| Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir. | Proteins 20070401 |
| Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. | The Journal of antimicrobial chemotherapy 20070401 |
| Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. | Therapeutic drug monitoring 20070401 |
| Antimalarial activity of sera from subjects taking HIV protease inhibitors. | AIDS (London, England) 20070330 |
| High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. | Journal of pharmaceutical and biomedical analysis 20070312 |
| Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. | British journal of clinical pharmacology 20070301 |
| Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. | Journal of acquired immune deficiency syndromes (1999) 20070301 |
| Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration. | The Journal of antimicrobial chemotherapy 20070301 |
| Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20070301 |
| Evaluation of an International Pharmacopoeia method for the analysis of saquinavir (mesilate) bulk drugs by liquid chromatography. | Journal of pharmaceutical and biomedical analysis 20070219 |
| Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. | The Journal of antimicrobial chemotherapy 20070201 |
| Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. | Journal of clinical pharmacology 20070201 |
| HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. | AIDS research and human retroviruses 20070201 |
| Dose reduction effective in alleviating symptoms of saquinavir toxicity. | International journal of STD & AIDS 20070201 |
| Update in HIV care. | Journal of general internal medicine 20070201 |
| Enhanced transport of P-glycoprotein substrate saquinavir in presence of thiolated chitosan. | Journal of drug targeting 20070201 |
| Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101 |
| In silico prediction of pregnane X receptor activators by machine learning approaches. | Molecular pharmacology 20070101 |
| Evaluation of 384-well formatted sample preparation technologies for regulated bioanalysis. | Rapid communications in mass spectrometry : RCM 20070101 |
| The activity of protease inhibitors against Giardia duodenalis and metronidazole-resistant Trichomonas vaginalis. | International journal of antimicrobial agents 20070101 |
| A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. | PLoS medicine 20070101 |
| HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? | PloS one 20070101 |
| Anti-HIV agents. Promising results from a saquinavir study. | TreatmentUpdate 20070101 |
| Anti-HIV agents. Starting therapy with saquinavir. | TreatmentUpdate 20070101 |
| Food consumption, cytochrome P450 3A4 (CYP3A4) presystemic inhibitors, and bioavailability of saquinavir. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20070101 |
| Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. | Antiviral therapy 20070101 |
| TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines? | Globalization and health 20070101 |
| AIDS in the Third World: how to stop the HIV infection? | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101 |
| Anti-HIV drugs. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101 |
| Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. | AIDS research and therapy 20070101 |
| Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children. | BMC infectious diseases 20070101 |
| Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. | Antiviral therapy 20070101 |
| Early prediction of median survival among a large AIDS surveillance cohort. | BMC public health 20070101 |
| Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20070101 |
| Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study. | AIDS research and therapy 20070101 |
| Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. | Rapid communications in mass spectrometry : RCM 20070101 |
| General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. | Clinical pharmacokinetics 20070101 |
| First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. | Clinical drug investigation 20070101 |
| Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005. | AIDS research and therapy 20070101 |
| Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES). | HIV clinical trials 20070101 |
| Medicinal importance of grapefruit juice and its interaction with various drugs. | Nutrition journal 20070101 |
| Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. | Cost effectiveness and resource allocation : C/E 20070101 |
| Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. | Current medicinal chemistry 20070101 |
| Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. | Antiviral therapy 20070101 |
| Targeting receptors, transporters and site of absorption to improve oral drug delivery. | Drug target insights 20070101 |
| NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines. | British journal of cancer 20061218 |
| Better lipid profile for Invirase. | AIDS patient care and STDs 20061201 |
| Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations. | Journal of molecular graphics & modelling 20061101 |
| The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. | The Journal of antimicrobial chemotherapy 20061101 |
| Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus. | Journal of virology 20061101 |
| Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors. | Research in microbiology 20061101 |
| Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. | Pharmaceutical research 20061101 |
| Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. | The Journal of antimicrobial chemotherapy 20061101 |
| Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). | The Journal of infectious diseases 20061101 |
| Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. | Journal of acquired immune deficiency syndromes (1999) 20061101 |
| Saquinavir and rifampicin for tuberculosis and AIDS: new considerations. | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20061101 |
| HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice. | Biomedical chromatography : BMC 20061001 |
| Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. | The Journal of pharmacology and experimental therapeutics 20060901 |
| HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. | Molecular pharmacology 20060901 |
| Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. | The Journal of antimicrobial chemotherapy 20060901 |
| Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. | The Journal of infectious diseases 20060901 |
| Discontinuation of highly active antiretroviral therapy leads to cryptococcal meningitis/choroiditis in an AIDS patient. | Optometry (St. Louis, Mo.) 20060901 |
| Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1. | Anti-cancer drugs 20060901 |
| Effect of quercetin on the plasma and intracellular concentrations of saquinavir in healthy adults. | Pharmacotherapy 20060901 |
| Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. | Journal of medicinal chemistry 20060824 |
| Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. | AIDS (London, England) 20060822 |
| Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. | AIDS (London, England) 20060822 |
| Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060801 |
| Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe. | Pharmacotherapy 20060801 |
| Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. | Pharmacotherapy 20060801 |
| Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. | Therapeutic drug monitoring 20060801 |
| Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses. | AIDS research and human retroviruses 20060801 |
| Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. | Pharmaceutical research 20060701 |
| A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. | The Journal of pharmacy and pharmacology 20060701 |
| Nephrotoxicity as a complication of antiretroviral therapy. | Advances in chronic kidney disease 20060701 |
| A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. | PLoS clinical trials 20060701 |
| Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. | HIV medicine 20060701 |
| Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. | AIDS (London, England) 20060626 |
| Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. | Antiviral research 20060601 |
| Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model. | Biophysical journal 20060601 |
| Antiretroviral drug resistance and routine therapy, Cameroon. | Emerging infectious diseases 20060601 |
| Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? | Therapeutic drug monitoring 20060601 |
| High HIV type 1 subtype diversity and few drug resistance mutations among seropositive people detected during the 2005 second generation HIV surveillance in Madagascar. | AIDS research and human retroviruses 20060601 |
| Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors. | Microbes and infection 20060601 |
| Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. | Biochemistry 20060502 |
| Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060501 |
| Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations. | The Journal of general virology 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. | HIV medicine 20060501 |
| Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. | Annals of neurology 20060501 |
| Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in-vitro and enhances its bioavailability in rats. | The Journal of pharmacy and pharmacology 20060501 |
| The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. | Haematologica 20060501 |
| Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. | AIDS (London, England) 20060424 |
| Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060415 |
| Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. | Bioorganic & medicinal chemistry letters 20060401 |
| Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. | The Journal of antimicrobial chemotherapy 20060401 |
| Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands. | Bioorganic & medicinal chemistry letters 20060401 |
| Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. | British journal of clinical pharmacology 20060401 |
| Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. | Journal of acquired immune deficiency syndromes (1999) 20060401 |
| MDR- and CYP3A4-mediated drug-herbal interactions. | Life sciences 20060327 |
| 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. | AIDS (London, England) 20060321 |
| Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir. | HIV medicine 20060301 |
| Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions. | HIV medicine 20060301 |
| In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. | Antimicrobial agents and chemotherapy 20060301 |
| [Screening of new HIV inhibitors based on the database of traditional Chinese medicine]. | Yao xue xue bao = Acta pharmaceutica Sinica 20060301 |
| API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. | The Journal of the Association of Physicians of India 20060301 |
| Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217 |
| Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202 |
| HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis. | Cell death and differentiation 20060201 |
| HIV drug-resistant strains as epidemiologic sentinels. | Emerging infectious diseases 20060201 |
| HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent. | Journal of medicinal chemistry 20060126 |
| Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings. | AIDS (London, England) 20060109 |
| Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. | AIDS (London, England) 20060102 |
| High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. | AIDS (London, England) 20060102 |
| Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. | Biomedical chromatography : BMC 20060101 |
| Saquinavir does not affect adipose tissue development or metabolic parameters in mice on high fat diet. | Thrombosis research 20060101 |
| Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. | Archives of medical research 20060101 |
| Antiviral hepatitis and antiretroviral drug interactions. | Journal of hepatology 20060101 |
| Saquinavir/Ritonavir: its evolution and current treatment role. | The AIDS reader 20060101 |
| Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. | Basic & clinical pharmacology & toxicology 20060101 |
| Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma. | Clinical chemistry and laboratory medicine 20060101 |
| DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes. | BMC infectious diseases 20060101 |
| Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. | BMC infectious diseases 20060101 |
| Lung cancer as an immune reconstitution disease in an HIV-1 positive man receiving HAART. | Postepy higieny i medycyny doswiadczalnej (Online) 20060101 |
| Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. | AIDS research and therapy 20060101 |
| Distinguishing HIV-1 drug resistance, accessory, and viral fitness mutations using conditional selection pressure analysis of treated versus untreated patient samples. | Biology direct 20060101 |
| Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. | Molecular pharmaceutics 20060101 |
| A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection. | Rapid communications in mass spectrometry : RCM 20060101 |
| Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. | HIV clinical trials 20060101 |
| Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients. | Antiviral therapy 20060101 |
| Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. | Retrovirology 20060101 |
| Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. | Radiation oncology (London, England) 20060101 |
| Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. | MedGenMed : Medscape general medicine 20060101 |
| HIV-2 Protease resistance defined in yeast cells. | Retrovirology 20060101 |
| Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir. | Antiviral therapy 20060101 |
| Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. | Antiviral therapy 20060101 |
| Gender: a possible determinant in dosing of dermatologic drugs--an overview. | Cutaneous and ocular toxicology 20060101 |
| Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses. | Microbiology and immunology 20060101 |
| Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. | HIV clinical trials 20060101 |
| Dendritic cell-mediated HIV-1 transmission to T cells of LAD-1 patients is impaired due to the defect in LFA-1. | Retrovirology 20060101 |
| Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. | Drugs 20060101 |
| Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport. | Bioconjugate chemistry 20060101 |
| Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein. | Retrovirology 20060101 |
| Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. | Clinical drug investigation 20060101 |
| Drug-herb interactions: eliminating toxicity with hard drug design. | Current pharmaceutical design 20060101 |
| Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART. | The Journal of eukaryotic microbiology 20060101 |
| Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. | PloS one 20060101 |
| Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand. | Cost effectiveness and resource allocation : C/E 20060101 |
| No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. | HIV clinical trials 20060101 |
| Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations. | HIV clinical trials 20060101 |
| Drug interactions. Coming soon--a new formulation of saquinavir (Invirase). | TreatmentUpdate 20060101 |
| [Development and validation of laboratory methods for antiretroviral quantitation using HPLC]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20060101 |
| Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. | Antiviral therapy 20060101 |
| Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors. | Bioinorganic chemistry and applications 20060101 |
| Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. | Journal of the International AIDS Society 20060101 |
| Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227 |
| Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215 |
| Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215 |
| The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. | Virology 20051205 |
| Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. | AIDS (London, England) 20051202 |
| Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. | Journal of medical virology 20051201 |
| No significant influence of saquinavir hard-gel capsule administration on pharmacokinetics of lopinavir in combination with ritonavir: a population approach. | Therapeutic drug monitoring 20051201 |
| Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. | The FEBS journal 20051201 |
| Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy. | International journal of STD & AIDS 20051201 |
| Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. | Clinical pharmacology and therapeutics 20051201 |
| Anti-retroviral therapy in HIV-infected patients: in vitro effects of AZT and saquinavir on the response of CD4 and CD8 lymphocytes to interleukin-7. | European cytokine network 20051201 |
| Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. | Therapeutics and clinical risk management 20051201 |
| In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. | The Journal of antimicrobial chemotherapy 20051101 |
| Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. | Journal of acquired immune deficiency syndromes (1999) 20051101 |
| Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study). | Journal of acquired immune deficiency syndromes (1999) 20051101 |
| A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. | AIDS research and human retroviruses 20051101 |
| Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. | The Journal of infectious diseases 20051015 |
| MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. | AIDS (London, England) 20051014 |
| Determination of antiretroviral agents in human serum by capillary electrophoresis. | Journal of chromatography. A 20051014 |
| Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. | International journal of pharmaceutics 20051013 |
| Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. | Antiviral research 20051001 |
| Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein. | Journal of virology 20051001 |
| Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. | The Pediatric infectious disease journal 20051001 |
| Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. | Current drug metabolism 20051001 |
| Grape fruit juice-drug interactions. | Pakistan journal of pharmaceutical sciences 20051001 |
| Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. | Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research 20051001 |
| Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism. | Bioorganic & medicinal chemistry letters 20050915 |
| HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. | Cancer research 20050915 |
| The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. | AIDS (London, England) 20050902 |
| In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. | The Journal of pharmacology and experimental therapeutics 20050901 |
| A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. | Journal of virological methods 20050901 |
| Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. | Journal of acquired immune deficiency syndromes (1999) 20050901 |
| Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. | European journal of clinical pharmacology 20050801 |
| Placental transfer of antiretroviral drugs. | Clinical pharmacology and therapeutics 20050801 |
| Functional role of P-glycoprotein in the human blood-placental barrier. | Clinical pharmacology and therapeutics 20050801 |
| Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis. | Chemotherapy 20050801 |
| Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort. | AIDS research and human retroviruses 20050801 |
| Potent saquinavir get European nod. | AIDS patient care and STDs 20050801 |
| Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. | Protein science : a publication of the Protein Society 20050701 |
| Antileishmanial activity of HIV protease inhibitors. | International journal of antimicrobial agents 20050701 |
| HIV leucoencephalopathy and TNFalpha expression in neurones. | Journal of neurology, neurosurgery, and psychiatry 20050701 |
| Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. | Biological & pharmaceutical bulletin 20050701 |
| FDA notifications. Roche issues letter about saquinavir. | AIDS alert 20050701 |
| Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. | Therapeutic drug monitoring 20050601 |
| TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. | Antimicrobial agents and chemotherapy 20050601 |
| Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay. | Antimicrobial agents and chemotherapy 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525 |
| Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor. | AIDS (London, England) 20050520 |
| Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors. | Journal of medicinal chemistry 20050519 |
| Establishment of a biological assay system for human retroviral protease activity. | Microbes and infection 20050501 |
| Emerging anti-HIV drugs. | Expert opinion on emerging drugs 20050501 |
| [Current status of HIV protease inhibitors]. | Yao xue xue bao = Acta pharmaceutica Sinica 20050501 |
| Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. | AIDS (London, England) 20050429 |
| [A further option in PI therapy. Approval of a new protease inhibitor in the USA]. | MMW Fortschritte der Medizin 20050425 |
| Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. | The Journal of antimicrobial chemotherapy 20050401 |
| Involvement of HIV-1 protease in virus-induced cell killing. | Antiviral research 20050401 |
| Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20050401 |
| Roche issues drug interaction warning. | AIDS alert 20050401 |
| Atazanavir affects saquinavir. | AIDS patient care and STDs 20050401 |
| Design of HIV-1 protease inhibitors active on multidrug-resistant virus. | Journal of medicinal chemistry 20050324 |
| P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. | The Journal of pharmacology and experimental therapeutics 20050301 |
| Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies. | Bioorganic & medicinal chemistry letters 20050301 |
| The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. | HIV medicine 20050301 |
| Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | Therapeutics and clinical risk management 20050301 |
| Mechanism-based inactivation of CYP3A by HIV protease inhibitors. | The Journal of pharmacology and experimental therapeutics 20050201 |
| Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. | Biophysical journal 20050201 |
| Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. | Journal of virology 20050201 |
| New drugs and dosage forms. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050201 |
| Blockade of HERG channels by HIV protease inhibitors. | Lancet (London, England) 20050201 |
| Pill burden reduced for saquinavir. | AIDS patient care and STDs 20050201 |
| Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. | AIDS (London, England) 20050128 |
| Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection. | AIDS (London, England) 20050128 |
| Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. | The Journal of biological chemistry 20050121 |
| Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. | British journal of clinical pharmacology 20050101 |
| Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101 |
| No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. | Annals of clinical microbiology and antimicrobials 20050101 |
| Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1. | International journal of immunopathology and pharmacology 20050101 |
| Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. | Lipids in health and disease 20050101 |
| Molecular strategies to inhibit HIV-1 replication. | Retrovirology 20050101 |
| Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations. | Journal of chemical information and modeling 20050101 |
| Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20050101 |
| The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. | Antiviral therapy 20050101 |
| Herb-drug interactions: a literature review. | Drugs 20050101 |
| Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. | HIV clinical trials 20050101 |
| Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. | HIV clinical trials 20050101 |
| Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. | BMC infectious diseases 20050101 |
| Drug-drug interactions and the pharmacotherapy of HIV infection. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101 |
| The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells. | Antiviral therapy 20050101 |
| Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20050101 |
| A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. | Antiviral therapy 20050101 |
| A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. | Antiviral therapy 20050101 |
| Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. | BMC infectious diseases 20050101 |
| Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). | HIV clinical trials 20050101 |
| Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. | Antiviral therapy 20050101 |
| Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. | International journal of immunopathology and pharmacology 20050101 |
| [New formulation--fewer tablets--optimal effect]. | Krankenpflege Journal 20050101 |
| Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients. | Clinical drug investigation 20050101 |
| Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225 |
| Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225 |
| Interaction between saquinavir and antimycotic drugs on C. albicans and C. neoformans strains. | Pharmacological research 20041201 |
| Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. | British journal of pharmacology 20041201 |
| Antiretrovirals as antimalarial agents. | The Journal of infectious diseases 20041201 |
| Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. | Oncology reports 20041201 |
| Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. | Annals of oncology : official journal of the European Society for Medical Oncology 20041201 |
| Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells. | The Journal of endocrinology 20041201 |
| The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. | Antiviral therapy 20041201 |
| Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. | Antiviral therapy 20041201 |
| Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy. | Journal of chemotherapy (Florence, Italy) 20041201 |
| Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. | Chemico-biological interactions 20041120 |
| Determination of saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography and the analytical error function. | Journal of pharmaceutical and biomedical analysis 20041119 |
| International AIDS Conference: compliance issues. | AIDS (London, England) 20041119 |
| Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. | AIDS (London, England) 20041119 |
| Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data. | Journal of medicinal chemistry 20041118 |
| Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. | Biochemistry 20041116 |
| CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. | AIDS (London, England) 20041105 |
| Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. | Proteins 20041101 |
| Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101 |
| Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20041101 |
| Atazanavir: A novel once-daily protease inhibitor. | Drugs of today (Barcelona, Spain : 1998) 20041101 |
| Pharmacokinetics of Telzir (fosamprenavir). | Journal of HIV therapy 20041101 |
| [Therapeutic strategies for HIV infection: clinical approach with boost antiproteases in adults]. | Medecine et maladies infectieuses 20041101 |
| The effectiveness of highly active antiretroviral therapy in HIV-infected patients. | Danish medical bulletin 20041101 |
| Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015 |
| HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. | Cancer research 20041015 |
| Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. | The Journal of antimicrobial chemotherapy 20041001 |
| Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. | British journal of clinical pharmacology 20041001 |
| Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. | Therapeutic drug monitoring 20041001 |
| Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation. | Antimicrobial agents and chemotherapy 20041001 |
| Miniature device for aqueous and non-aqueous solubility measurements during drug discovery. | Pharmaceutical research 20041001 |
| Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors. | Pharmaceutical research 20041001 |
| Binding of anti-HIV drugs to human serum albumin. | IUBMB life 20041001 |
| Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. | AIDS (London, England) 20040924 |
| Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. | HIV medicine 20040901 |
| The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. | Journal of acquired immune deficiency syndromes (1999) 20040801 |
| Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. | Journal of virology 20040801 |
| Resistance to HIV protease inhibitors: mechanisms and clinical consequences. | Current drug metabolism 20040801 |
| Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. | American journal of obstetrics and gynecology 20040801 |
| Electronic transduction of HIV-1 drug resistance in AIDS patients. | Chembiochem : a European journal of chemical biology 20040705 |
| Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. | The Journal of pharmacology and experimental therapeutics 20040701 |
| HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). | The Journal of pharmacology and experimental therapeutics 20040701 |
| Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. | Journal of clinical pharmacology 20040701 |
| Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20040701 |
| Atazanavir: a new protease inhibitor to treat HIV infection. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701 |
| Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. | AIDS (London, England) 20040618 |
| High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615 |
| Antiviral drugs in current clinical use. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601 |
| The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. | Antiviral therapy 20040601 |
| Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. | Antiviral therapy 20040601 |
| Multidrug resistance protein 1-mediated transport of saquinavir by microglia. | Neuroreport 20040519 |
| Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART. | Medical science monitor : international medical journal of experimental and clinical research 20040501 |
| Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. | Pharmacotherapy 20040501 |
| Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. | Pharmaceutical research 20040501 |
| Practical aspects of transporter model systems: a case study involving SQV. | Drug metabolism reviews 20040501 |
| [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance]. | MMW Fortschritte der Medizin 20040426 |
| [FPV plus SQV plus a mini-dose ritonavir. 'Double boosting with compatible partners]. | MMW Fortschritte der Medizin 20040426 |
| Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors. | The Journal of organic chemistry 20040402 |
| Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. | The Journal of infectious diseases 20040401 |
| HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. | Molecular cancer therapeutics 20040401 |
| Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. | Journal of acquired immune deficiency syndromes (1999) 20040401 |
| Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). | Antiviral therapy 20040401 |
| Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. | Emerging infectious diseases 20040401 |
| P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line. | The new microbiologica 20040401 |
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? | The Journal of infectious diseases 20040315 |
| Optimizing dosing strategies for the combination of atazanavir plus saquinavir. | AIDS (London, England) 20040305 |
| Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. | The Journal of pharmacology and experimental therapeutics 20040301 |
| Protease inhibitors modulate apoptosis in mesangial cells derived from a mouse model of HIVAN. | Kidney international 20040301 |
| The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. | Journal of clinical pharmacology 20040301 |
| Oral contraception does not alter single dose saquinavir pharmacokinetics in women. | British journal of clinical pharmacology 20040301 |
| Combo approved for HIV treatment. | The Nurse practitioner 20040301 |
| In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes. | Pharmaceutical research 20040301 |
| Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. | Pharmaceutical research 20040301 |
| Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20040301 |
| Boosted saquinavir approved. | AIDS patient care and STDs 20040301 |
| Simultaneous determination of indinavir, ritonavir and saquinavir in plasma by high-performance liquid chromatography. | Journal of the Formosan Medical Association = Taiwan yi zhi 20040301 |
| Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir. | International journal of antimicrobial agents 20040301 |
| Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. | Xenobiotica; the fate of foreign compounds in biological systems 20040301 |
| Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. | AIDS (London, England) 20040220 |
| Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity. | Organic & biomolecular chemistry 20040207 |
| Toward the development of a structurally novel class of chiral auxiliaries. Conformational properties of the aldol adducts of oxadiazinones: observation of unusual shielding effects. | The Journal of organic chemistry 20040206 |
| Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. | Antimicrobial agents and chemotherapy 20040201 |
| Evaluation of factors to decrease plasma concentration of an HIV protease inhibitor, saquinavir in ethanol-treated rats. | Biological & pharmaceutical bulletin 20040201 |
| Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20040201 |
| Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. | Antiviral therapy 20040201 |
| Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. | Antiviral therapy 20040201 |
| Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. | Molecular pharmaceutics 20040112 |
| Determinants of long-term highly active antiretroviral treatment efficacy. | HIV medicine 20040101 |
| Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals. | The new microbiologica 20040101 |
| A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells. | American journal of therapeutics 20040101 |
| A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). | HIV clinical trials 20040101 |
| Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. | Journal of molecular recognition : JMR 20040101 |
| Synthesis and evaluation of a novel synthetic phosphocholine lipid-AZT conjugate that double-targets wild-type and drug resistant variants of HIV. | Nucleosides, nucleotides & nucleic acids 20040101 |
| Pharmacokinetic enhancement of protease inhibitor therapy. | Clinical pharmacokinetics 20040101 |
| FDA approves SQV/r. | IAPAC monthly 20040101 |
| Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2). | BMC medicine 20040101 |
| Peptidomimetic inhibitors of HIV protease. | Current topics in medicinal chemistry 20040101 |
| HIV-1 gene expression: lessons from provirus and non-integrated DNA. | Retrovirology 20040101 |
| Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites. | Journal of medical Internet research 20040101 |
| Vascular endothelial toxicity induced by HIV protease inhibitor: evidence of oxidant-related dysfunction and apoptosis. | Cardiovascular toxicology 20040101 |
| Practical guidelines to interpret plasma concentrations of antiretroviral drugs. | Clinical pharmacokinetics 20040101 |
| Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction. | Clinical pharmacokinetics 20040101 |
| Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. | Bioconjugate chemistry 20040101 |
| Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3. | Retrovirology 20040101 |
| Pharmacokinetics of antiretrovirals in pregnant women. | Clinical pharmacokinetics 20040101 |
| Anti-HIV agents. A protease-only regimen--Kaletra and saquinavir. | TreatmentUpdate 20040101 |
| Anti-HIV agents. No interaction between tenofovir and saquinavir. | TreatmentUpdate 20040101 |
| Anti-HIV agents. Saquinavir--switching from Fortovase to Invirase. | TreatmentUpdate 20040101 |
| Anti-HIV agents. Saquinavir with fosamprenavir. | TreatmentUpdate 20040101 |
| Anti-HIV agents. Atazanavir and saquinavir. | TreatmentUpdate 20040101 |
| Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults. | Therapeutic drug monitoring 20031201 |
| Stability of extemporaneously prepared saquinavir formulations. | Journal of clinical pharmacy and therapeutics 20031201 |
| Therapeutic dose of HIV-1 protease inhibitor saquinavir does not permanently influence early insulin signaling. | Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20031201 |
| A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20031201 |
| HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. | The Journal of biological chemistry 20031128 |
| Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. | Biochemistry 20031125 |
| Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. | British journal of cancer 20031117 |
| Pharmacokinetic characterization of a human immunodeficiency virus protease inhibitor, saquinavir, during ethanol intake in rats. | Biopharmaceutics & drug disposition 20031101 |
| Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. | British journal of clinical pharmacology 20031101 |
| [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir]. | Medicina clinica 20031025 |
| Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. | AIDS (London, England) 20031017 |
| Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. | AIDS (London, England) 20031017 |
| Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. | Journal of lipid research 20031001 |
| The effect of cell culture conditions on saquinavir transport through, and interactions with, MDCKII cells overexpressing hMDR1. | Journal of pharmaceutical sciences 20031001 |
| Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. | Antimicrobial agents and chemotherapy 20031001 |
| Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults. | Therapeutic drug monitoring 20031001 |
| Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. | HIV medicine 20031001 |
| Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. | AIDS (London, England) 20030926 |
| Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum. | The Journal of antimicrobial chemotherapy 20030901 |
| Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. | The Journal of antimicrobial chemotherapy 20030901 |
| Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. | The Journal of infectious diseases 20030901 |
| In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir. | Antimicrobial agents and chemotherapy 20030901 |
| Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. | The Lancet. Oncology 20030901 |
| The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. | The Journal of endocrinology 20030901 |
| The binding of HIV-1 protease inhibitors to human serum proteins. | Biophysical chemistry 20030901 |
| Contraindicated antiretroviral drug combinations. | New Jersey medicine : the journal of the Medical Society of New Jersey 20030901 |
| Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20030901 |
| Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma. | Leukemia & lymphoma 20030901 |
| Boosted PIs: competition hots up. | The AIDS reader 20030901 |
| Virological rebound after suppression on highly active antiretroviral therapy. | AIDS (London, England) 20030815 |
| The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. | Journal of acquired immune deficiency syndromes (1999) 20030815 |
| Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20030815 |
| HIV protease inhibitors as new treatment options for Kaposi's sarcoma. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20030801 |
| Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. | AIDS (London, England) 20030725 |
| Indinavir reduces Cryptosporidium parvum infection in both in vitro and in vivo models. | International journal for parasitology 20030701 |
| Rapid enzymatic test for phenotypic HIV protease drug resistance. | Biological chemistry 20030701 |
| Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). | The Journal of biological chemistry 20030627 |
| Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. | The Journal of infectious diseases 20030615 |
| Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. | Journal of immunology (Baltimore, Md. : 1950) 20030615 |
| A review of low-dose ritonavir in protease inhibitor combination therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030615 |
| Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. | AIDS (London, England) 20030613 |
| Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. | Therapeutic drug monitoring 20030601 |
| Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. | Therapeutic drug monitoring 20030601 |
| [Comparison of pharmacokinetics of saquinavir soft-gel capsule (SQV-SGC) combined with ritonavir (RTV), SQV hard-gel capsule with RTV, and SQV-SGC alone]. | Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20030601 |
| Comparison of nine resistance interpretation systems for HIV-1 genotyping. | Antiviral therapy 20030601 |
| Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. | Antiviral therapy 20030601 |
| Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525 |
| Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. | Chemotherapy 20030501 |
| Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. | Clinical pharmacology and therapeutics 20030501 |
| Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. | Antiviral research 20030501 |
| Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. | Seminars in liver disease 20030501 |
| Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. | AIDS patient care and STDs 20030501 |
| ['Double boosting' passes the test. LPV/r plus SQV in complicated salvage situation]. | MMW Fortschritte der Medizin 20030428 |
| Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425 |
| Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. | Journal of medicinal chemistry 20030424 |
| Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains. | Journal of medicinal chemistry 20030424 |
| Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20030415 |
| Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects. | Journal of acquired immune deficiency syndromes (1999) 20030401 |
| Sildenafil does not alter nelfinavir pharmacokinetics. | Therapeutic drug monitoring 20030401 |
| Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. | HIV medicine 20030401 |
| Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases. | Medical mycology 20030401 |
| Control of human immunodeficiency virus type-1 protease activity in insect cells expressing Gag-Pol rescues assembly of immature but not mature virus-like particles. | Virology 20030330 |
| New anti-human immunodeficiency virus type 1 6-aminoquinolones: mechanism of action. | Antimicrobial agents and chemotherapy 20030301 |
| Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans. | Journal of medical microbiology 20030301 |
| Molecular dynamics study of the connection between flap closing and binding of fullerene-based inhibitors of the HIV-1 protease. | Biochemistry 20030211 |
| Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205 |
| Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205 |
| Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. | The Journal of pharmacology and experimental therapeutics 20030201 |
| Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20030201 |
| Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats. | Biological & pharmaceutical bulletin 20030201 |
| Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Journal of mass spectrometry : JMS 20030201 |
| Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up. | Antiviral therapy 20030201 |
| [HIV protease inhibitors for the treatment of Kaposi's sarcoma]. | Recenti progressi in medicina 20030201 |
| A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. | Biochemistry 20030128 |
| Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors. | European journal of medical research 20030128 |
| Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115 |
| Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. | AIDS (London, England) 20030103 |
| Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. | The Journal of pharmacology and experimental therapeutics 20030101 |
| Predicting HIV drug resistance with neural networks. | Bioinformatics (Oxford, England) 20030101 |
| The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. | Journal of lipid research 20030101 |
| Quantitative determination of saquinavir from Caco-2 cell monolayers by HPLC-UV. High performance liquid chromatography. | Biomedical chromatography : BMC 20030101 |
| In vitro activity of potential anti-poxvirus agents. | Antiviral research 20030101 |
| Lopinavir/ritonavir: a review of its use in the management of HIV infection. | Drugs 20030101 |
| Saquinavir: a review of its use in boosted regimens for treating HIV infection. | Drugs 20030101 |
| Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. | HIV clinical trials 20030101 |
| Saquinavir/low-dose ritonavir: its use in HIV infection. | AIDS reviews 20030101 |
| Pharmacokinetic interactions with rifampicin : clinical relevance. | Clinical pharmacokinetics 20030101 |
| Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. | Health and quality of life outcomes 20030101 |
| Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology. | Digestion 20030101 |
| The effect of human immunodeficiency virus-1 protease inhibitors on the toxicity of a variety of cells. | In vitro cellular & developmental biology. Animal 20030101 |
| Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome? | Scandinavian journal of infectious diseases 20030101 |
| Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains. | Journal of molecular biology 20021206 |
| Diurnal variation of plasma protease inhibitor concentrations. | AIDS (London, England) 20021206 |
| Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. | Journal of medicinal chemistry 20021205 |
| Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. | Journal of medical virology 20021201 |
| Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. | Drug metabolism and disposition: the biological fate of chemicals 20021201 |
| Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. | International journal of antimicrobial agents 20021201 |
| Pharmacokinetics of saquinavir co-administered with cimetidine. | The Journal of antimicrobial chemotherapy 20021201 |
| Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. | Antiviral therapy 20021201 |
| Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. | AIDS (London, England) 20021122 |
| Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021115 |
| New anti-HIV agents and targets. | Medicinal research reviews 20021101 |
| Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. | Diabetes 20021101 |
| Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O. | Journal of clinical microbiology 20021101 |
| Transport of HIV-protease inhibitors across 1 alpha,25di-hydroxy vitamin D3-treated Calu-3 cell monolayers: modulation of P-glycoprotein activity. | Pharmaceutical research 20021101 |
| Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers. | Pharmaceutical research 20021101 |
| Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. | Journal of pharmaceutical and biomedical analysis 20021015 |
| The secreted aspartic proteinases as a new target in the therapy of candidiasis. | Current drug targets 20021001 |
| Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance. | Therapeutic drug monitoring 20021001 |
| P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. | The Journal of antimicrobial chemotherapy 20021001 |
| Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy. | The Journal of rheumatology 20021001 |
| Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. | HIV medicine 20021001 |
| Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study. | HIV medicine 20021001 |
| Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz. | HIV medicine 20021001 |
| In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome. | Mitochondrion 20021001 |
| Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. | AIDS (London, England) 20020927 |
| Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia. | AIDS research and human retroviruses 20020920 |
| The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. | Cancer research 20020915 |
| Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. | The Journal of infectious diseases 20020901 |
| [Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report]. | Archivos de la Sociedad Espanola de Oftalmologia 20020901 |
| The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. | British journal of clinical pharmacology 20020901 |
| Concentrations of protease inhibitors in cord blood after in utero exposure. | The Pediatric infectious disease journal 20020901 |
| Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection. | Antiviral therapy 20020901 |
| Predictors of treatment failure during highly active antiretroviral therapy (racing trial). | European journal of medical research 20020830 |
| Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy. | Bioorganic & medicinal chemistry letters 20020805 |
| Garlic supplements and saquinavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020801 |
| Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. | The Journal of pharmacology and experimental therapeutics 20020801 |
| Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission. | Journal of acquired immune deficiency syndromes (1999) 20020801 |
| Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. | Therapeutic drug monitoring 20020801 |
| Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. | Clinical pharmacology and therapeutics 20020801 |
| Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV. | British journal of clinical pharmacology 20020801 |
| Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). | AIDS (London, England) 20020726 |
| New developments in anti-HIV chemotherapy. | Biochimica et biophysica acta 20020718 |
| Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715 |
| Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. | JAMA 20020710 |
| Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. | Biochemistry 20020709 |
| Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds. | Bioorganic & medicinal chemistry letters 20020708 |
| Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance. | Proteins 20020701 |
| In vitro antiviral interaction of lopinavir with other protease inhibitors. | Antimicrobial agents and chemotherapy 20020701 |
| Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure. | Journal of medical virology 20020701 |
| Pharmacokinetics of saquinavir in children during long term treatment. | The Pediatric infectious disease journal 20020701 |
| Garlic supplements can impede HIV medication. | AIDS (London, England) 20020614 |
| Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry. | Biomedical chromatography : BMC 20020601 |
| High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. | Therapeutic drug monitoring 20020601 |
| Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. | British journal of clinical pharmacology 20020601 |
| Functional expression and localization of P-glycoprotein at the blood brain barrier. | Microscopy research and technique 20020601 |
| Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. | Pharmaceutical research 20020601 |
| Saquinavir soft-gel capsules (Fortovase) give lower exposure than expected, even after a high-fat breakfast. | Pharmacy world & science : PWS 20020601 |
| Select HIV protease inhibitors alter bone and fat metabolism ex vivo. | The Journal of biological chemistry 20020531 |
| A neutravidin-based assay for reverse transcriptase suitable for high throughput screening of retroviral activity. | Journal of biochemistry and molecular biology 20020531 |
| [When nucleoside analogs cannot be tolerated. HIV therapy with booster]. | MMW Fortschritte der Medizin 20020509 |
| Inhibition of morphine-potentiated HIV-1 replication in peripheral blood mononuclear cells with the nuclease-resistant 2-5A agonist analog, 2-5A(N6B). | Journal of acquired immune deficiency syndromes (1999) 20020501 |
| Male sexual dysfunction associated with antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20020501 |
| A randomized, open-label, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advanced AIDS patients. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20020501 |
| Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study. | Journal of acquired immune deficiency syndromes (1999) 20020415 |
| Transplacental passage of protease inhibitors at delivery. | AIDS (London, England) 20020412 |
| [More transparency facilities drug choice in general practice. Booster regimens in direct comparison]. | MMW Fortschritte der Medizin 20020409 |
| Antiviral activity of UIC-PI, a novel inhibitor of the human immunodeficiency virus type 1 protease. | Antiviral research 20020401 |
| Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. | Therapeutic drug monitoring 20020401 |
| The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. | HIV medicine 20020401 |
| Long-term maintenance antiretroviral therapy with saquinavir hard gel, after voluntary abandonment of successful induction HAART. | Journal of chemotherapy (Florence, Italy) 20020401 |
| The utility of inhibitory quotients in determining the relative potency of protease inhibitors. | AIDS (London, England) 20020329 |
| Eruptive angiolipomas associated with antiretroviral therapy. | AIDS (London, England) 20020329 |
| Garlic supplements and HIV medication. | American family physician 20020315 |
| Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles. | Virology 20020315 |
| Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. | AIDS (London, England) 20020308 |
| Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. | AIDS (London, England) 20020308 |
| [Acute coronary syndromes in patients treated with HIV protease inhibitors]. | Presse medicale (Paris, France : 1983) 20020302 |
| HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. | Nature medicine 20020301 |
| Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. | Clinical pharmacology and therapeutics 20020301 |
| Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. | Journal of pharmaceutical sciences 20020301 |
| [Comparison between HIV-1-infected hemophiliacs and non-hemophiliacs on survival and clinical courses after starting highly active antiretroviral therapy]. | Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases 20020301 |
| Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor. | The Pediatric infectious disease journal 20020301 |
| A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. | Journal of virology 20020201 |
| Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. | Journal of medical virology 20020201 |
| Development of a chromatographic method for the determination of saquinavir in plasma samples of HIV patients. | Biomedical chromatography : BMC 20020201 |
| In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. | The Journal of pharmacy and pharmacology 20020201 |
| Garlic supplements can impede HIV medication. | Journal of the American College of Surgeons 20020201 |
| Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. | British journal of clinical pharmacology 20020201 |
| NIH studies link between saquinavir and garlic pills. | AIDS alert 20020201 |
| Efficacy of highly active antiretroviral therapy in HIV-1 infected children. | The Lancet. Infectious diseases 20020201 |
| Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy. | AIDS (London, England) 20020125 |
| Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. | AIDS (London, England) 20020125 |
| The effect of garlic supplements on the pharmacokinetics of saquinavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020115 |
| Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020115 |
| Effects of antiretroviral drug combinations on the differentiation of adipocytes. | AIDS (London, England) 20020104 |
| Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. | AIDS (London, England) 20020104 |
| The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. | The Journal of endocrinology 20020101 |
| CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. | Xenobiotica; the fate of foreign compounds in biological systems 20020101 |
| Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation. | Acta pharmacologica Sinica 20020101 |
| Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1-infected children. | Scandinavian journal of infectious diseases 20020101 |
| A SOFM approach to predicting HIV drug resistance. | Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 20020101 |
| Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. | Arzneimittel-Forschung 20020101 |
| Retroviral proteases. | Genome biology 20020101 |
| The effect of HAART on humoral immune response in primary HIV-1 infected patients. | Journal of biological regulators and homeostatic agents 20020101 |
| Saquinavir with low-dose ritonavir twice daily. | TreatmentUpdate 20020101 |
| Invirase vs. Fortovase: unexpected results? | TreatmentUpdate 20020101 |
| Saquinavir once daily. | TreatmentUpdate 20020101 |
| Could cimetidine be used as a booster? | TreatmentUpdate 20020101 |
| Food-drug interactions. | Drugs 20020101 |
| Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats. | Antiviral chemistry & chemotherapy 20020101 |
| Resistance profiles of cyclic and linear inhibitors of HIV-1 protease. | Antiviral chemistry & chemotherapy 20020101 |
| [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ]. | Therapie 20020101 |
| Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. | BMC infectious diseases 20020101 |
| Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). | The Body positive 20020101 |
| Aphtous stomatitis in a patient with Behçet's disease and HIV was associated with an increased HIV load. | Clinical and experimental rheumatology 20020101 |
| Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | Clinical pharmacokinetics 20020101 |
| Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report. | Annals of clinical microbiology and antimicrobials 20020101 |
| Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. | HIV clinical trials 20020101 |
| Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitors (PI's) and cytotoxic drugs. | Annali dell'Istituto superiore di sanita 20020101 |
| Management of protease inhibitor-associated hyperlipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. | The Journal of biological chemistry 20011221 |
| Garlic reduces saquinavir blood levels 50%; may affect other drugs. | AIDS treatment news 20011221 |
| Has there been a decrease in the prevalence of mood disorders in HIV-seropositive individuals since the introduction of combination therapy? | European psychiatry : the journal of the Association of European Psychiatrists 20011201 |
| Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection. | Therapeutic drug monitoring 20011201 |
| Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. | Antiviral therapy 20011201 |
| Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations. | Antiviral therapy 20011201 |
| Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study). | Antiviral therapy 20011201 |
| [Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols]. | Acta pharmaceutica Hungarica 20011201 |
| Drugs for HIV infection. | The Medical letter on drugs and therapeutics 20011126 |
| HIV protease inhibitors reduce IL-2 release from normal human phytohaemagglutinin-activated T cells. | AIDS (London, England) 20011123 |
| The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors. | Journal of medicinal chemistry 20011122 |
| Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. | Carbohydrate research 20011121 |
| Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. | The Journal of infectious diseases 20011115 |
| Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. | AIDS (London, England) 20011109 |
| New developments in anti-HIV chemotherapy. | Current medicinal chemistry 20011101 |
| DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. | Antimicrobial agents and chemotherapy 20011101 |
| Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy. | Metabolism: clinical and experimental 20011101 |
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. | Lancet (London, England) 20011020 |
| Effects of the membrane dipole potential on the interaction of saquinavir with phospholipid membranes and plasma membrane receptors of Caco-2 cells. | The Journal of biological chemistry 20011019 |
| HIV-protease inhibitors alter retinoic acid synthesis. | AIDS (London, England) 20011019 |
| Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011015 |
| Functional expression of P-glycoprotein in rat brain microglia. | The Journal of pharmacology and experimental therapeutics 20011001 |
| HIV-1 induction-maintenance at the lymph node level: the 'Apollo-97' Study. | Journal of acquired immune deficiency syndromes (1999) 20011001 |
| Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells. | Journal of acquired immune deficiency syndromes (1999) 20011001 |
| [Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001]. | Presse medicale (Paris, France : 1983) 20010922 |
| Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. | The Journal of biological chemistry 20010914 |
| Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution. | Journal of medicinal chemistry 20010913 |
| Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. | Archives of internal medicine 20010910 |
| Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. | The Journal of biological chemistry 20010907 |
| Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. | AIDS (London, England) 20010907 |
| Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | Antiviral research 20010901 |
| Antiretroviral drug concentrations in semen of HIV-infected men: differential penetration of indinavir, ritonavir and saquinavir. | The Journal of antimicrobial chemotherapy 20010901 |
| Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. | AIDS research and human retroviruses 20010901 |
| Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. | British journal of clinical pharmacology 20010901 |
| Searching for the right dose of ritonavir-saquinavir. | TreatmentUpdate 20010901 |
| Protection against experimental autoimmune encephalomyelitis by a proteasome modulator. | Journal of neuroimmunology 20010830 |
| Effect of Saquinavir on proliferation and telomerase activity of human peripheral blood mononuclear cells. | Life sciences 20010817 |
| Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. | Blood 20010815 |
| Antiviral drugs: current state of the art. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801 |
| HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. | Therapeutic drug monitoring 20010801 |
| Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. | Therapeutic drug monitoring 20010801 |
| A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. | Clinical pharmacology and therapeutics 20010801 |
| Saquinavir up-regulates telomerase activity in lymphocytes activated with monoclonal antibodies against CD3/CD28. | Journal of chemotherapy (Florence, Italy) 20010801 |
| P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? | AIDS (London, England) 20010727 |
| Synthesis of a chiral aziridine derivative as a versatile intermediate for HIV protease inhibitors. | Organic letters 20010726 |
| High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. | Journal of chromatography. B, Biomedical sciences and applications 20010715 |
| Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy. | Journal of chromatography. A 20010713 |
| CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART. | The British journal of ophthalmology 20010701 |
| Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. | The Pediatric infectious disease journal 20010701 |
| HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. | FEMS immunology and medical microbiology 20010701 |
| Predictors of protease inhibitor-associated adverse events. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20010701 |
| Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. | American journal of obstetrics and gynecology 20010701 |
| The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. | Archives of biochemistry and biophysics 20010615 |
| Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010615 |
| Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. | AIDS research and human retroviruses 20010610 |
| Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir. | The Journal of organic chemistry 20010601 |
| The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. | Journal of acquired immune deficiency syndromes (1999) 20010601 |
| Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. | Journal of acquired immune deficiency syndromes (1999) 20010601 |
| Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998. | Journal of acquired immune deficiency syndromes (1999) 20010601 |
| The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. | British journal of clinical pharmacology 20010601 |
| The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients. | Journal of the American Dietetic Association 20010601 |
| Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. | Antiviral therapy 20010601 |
| Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response. | Antiviral therapy 20010601 |
| Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. | AIDS (London, England) 20010525 |
| Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. | International journal of pharmaceutics 20010507 |
| Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Biomedical sciences and applications 20010505 |
| Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. | AIDS (London, England) 20010504 |
| Regulation of expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. | Endocrinology 20010501 |
| Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. | European journal of biochemistry 20010501 |
| Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine. | Bioorganic & medicinal chemistry 20010501 |
| The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. | European journal of clinical pharmacology 20010501 |
| [HIV-HBV coinfection and the liver]. | Gastroenterologie clinique et biologique 20010501 |
| A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir. | Journal of acquired immune deficiency syndromes (1999) 20010415 |
| High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. | Journal of acquired immune deficiency syndromes (1999) 20010415 |
| Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology. | Analytical biochemistry 20010415 |
| Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | Journal of chromatography. A 20010413 |
| Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. | AIDS (London, England) 20010413 |
| Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. | AIDS research and human retroviruses 20010410 |
| [Improving the pharmacokinetics of protease inhibitors in a more innovative manner. HIV drugs administered in a more clever way]. | MMW Fortschritte der Medizin 20010402 |
| P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. | Molecular pharmacology 20010401 |
| Intracellular concentration of the HIV protease inhibitors indinavir and saquinavir in human endothelial cells. | The Journal of antimicrobial chemotherapy 20010401 |
| An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. | Controlled clinical trials 20010401 |
| Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. | Molecular therapy : the journal of the American Society of Gene Therapy 20010401 |
| Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. | The Journal of infection 20010401 |
| Principles and practice of HIV-protease inhibitor pharmacoenhancement. | HIV medicine 20010401 |
| Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. | AIDS (London, England) 20010330 |
| Elevated alpha-1-acid glycoprotein reduces the volume of distribution and systemic clearance of saquinavir. | Drug metabolism and disposition: the biological fate of chemicals 20010301 |
| A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease. | Acta crystallographica. Section D, Biological crystallography 20010301 |
| The safety and antiviral effect of protease inhibitors in children. | Pharmacotherapy 20010301 |
| Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study. | AIDS patient care and STDs 20010301 |
| A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. | International journal of clinical pharmacology and therapeutics 20010301 |
| Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active antiretroviral therapy. | AIDS (London, England) 20010216 |
| Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. | The Journal of infectious diseases 20010215 |
| Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. | Drug metabolism and disposition: the biological fate of chemicals 20010201 |
| Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20010201 |
| Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study. | International journal of STD & AIDS 20010201 |
| [Long-term immunologic response in HIV-infected patients with CD4 cell counts </= 50/mm3 when initiating protease inhibitor therapy]. | Annales de medecine interne 20010201 |
| Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient. | Nephron 20010201 |
| Pharmacology and clinical experience with saquinavir. | Expert opinion on pharmacotherapy 20010201 |
| [Resistance to protease inhibitors]. | Enfermedades infecciosas y microbiologia clinica 20010201 |
| The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. | AIDS (London, England) 20010126 |
| Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. | AIDS research and human retroviruses 20010120 |
| The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. | AIDS (London, England) 20010105 |
| Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro. | British journal of clinical pharmacology 20010101 |
| Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. | Journal of clinical laboratory analysis 20010101 |
| Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20010101 |
| Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission. | Journal of acquired immune deficiency syndromes (1999) 20010101 |
| Ritonavir-induced carbamazepine toxicity. | The Annals of pharmacotherapy 20010101 |
| Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma. | In vivo (Athens, Greece) 20010101 |
| Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. | Scandinavian journal of infectious diseases 20010101 |
| Saquinavir soft gelatin capsule: a comparative safety review. | Drug safety 20010101 |
| Structure-based design of non-peptide HIV protease inhibitors. | Farmaco (Societa chimica italiana : 1989) 20010101 |
| New developments in anti-HIV chemotherapy. | Farmaco (Societa chimica italiana : 1989) 20010101 |
| [Drug interactions with antiretroviral agents]. | Therapie 20010101 |
| Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases. | Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal 20010101 |
| Development of HIV protease inhibitors: a survey. | Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20010101 |
| A peptide inhibitor of HIV-1 protease using alpha, beta- dehydro residues: a structure based computer model. | Indian journal of biochemistry & biophysics 20010101 |
| Garlic supplements found to lower saquinavir levels. | TreatmentUpdate 20010101 |
| From grapefruit juice to ritonavir. | TreatmentUpdate 20010101 |
| A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients. | HIV clinical trials 20010101 |
| The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study. | HIV clinical trials 20010101 |
| Effect of prior nucleoside use on the two-year virological response to an initial protease inhibitor regimen in HIV-infected patients. | HIV clinical trials 20010101 |
| Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC. | Clinical laboratory 20010101 |
| Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study. | HIV clinical trials 20010101 |
| Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients. | HIV clinical trials 20010101 |
| The use of efavirenz as a part of late rescue antiretroviral treatment. | HIV clinical trials 20010101 |
| MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. | HIV medicine 20010101 |
| Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients. | HIV medicine 20010101 |
| Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomized trial and an observational cohort. | HIV medicine 20010101 |
| Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy. | HIV clinical trials 20010101 |
| Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. | HIV clinical trials 20010101 |
| 'In vitro' antifungal activity of protease inhibitors. | Mycopathologia 20010101 |
| Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20001215 |
| Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. | Biological & pharmaceutical bulletin 20001201 |
| Inhibition of HIV-1 protease by a boron-modified polypeptide. | Biochemical pharmacology 20001001 |
| Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. | AIDS (London, England) 20000908 |
| Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. | Journal of medicinal chemistry 20000907 |
| In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. | Antimicrobial agents and chemotherapy 20000901 |
| BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. | Antimicrobial agents and chemotherapy 20000801 |
| Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir. | Journal of virology 20000801 |
| Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. | Antiviral chemistry & chemotherapy 20000701 |
| Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds. | Bioorganic & medicinal chemistry letters 20000605 |
| A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. | Journal of virology 20000501 |
| In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. | The Journal of infectious diseases 20000501 |
| 2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors. | Journal of medicinal chemistry 20000323 |
| 5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease. | Journal of medicinal chemistry 20000309 |
| Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. | Antiviral chemistry & chemotherapy 20000301 |
| Protease inhibitors: current status and future prospects. | Journal of medicinal chemistry 20000210 |
| In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. | AIDS (London, England) 20000107 |
| Decreased methadone effect after ritonavir initiation. | Pharmacotherapy 20000101 |
| Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. | The American journal of medicine 19991201 |
| Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors. | Archiv der Pharmazie 19991101 |
| Renin-angiotensin system inhibition in a patient having an overdose of HIV protease inhibitor. | AIDS (London, England) 19991001 |
| Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors. | Journal of medicinal chemistry 19990923 |
| Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. | The Journal of biological chemistry 19990820 |
| Hydroxyurea-induced neurotoxicity in HIV disease. | AIDS (London, England) 19990820 |
| A new class of anti-HIV agents: synthesis and activity of conjugates of HIV protease inhibitors with a reverse transcriptase inhibitor. | Bioorganic & medicinal chemistry letters 19990322 |
| The HIV type 1 protease inhibitor saquinavir can select for multiple mutations that confer increasing resistance. | AIDS research and human retroviruses 19990301 |
| Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. | Antiviral chemistry & chemotherapy 19990301 |
| Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. | Antimicrobial agents and chemotherapy 19990201 |
| Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors. | Archiv der Pharmazie 19990101 |
| Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production. | FEBS letters 19981228 |
| Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. | Chemical research in toxicology 19981201 |
| Anti-HIV activity and mechanism of action of macrocyclic diamide SRR-SB3. | The Journal of pharmacy and pharmacology 19981201 |
| Lipid lowering therapy in patients with HIV infection. | Lancet (London, England) 19981128 |
| [Nephrotoxicity of ritonavir]. | Presse medicale (Paris, France : 1983) 19981114 |
| Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. | Biochemistry 19981027 |
| Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. | Virology 19981025 |
| Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. | AIDS (London, England) 19981022 |
| Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. | Antimicrobial agents and chemotherapy 19981001 |
| Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. | Chemistry & biology 19981001 |
| In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. | Journal of virology 19980901 |
| Renal calculi developing de novo in a patient taking saquinavir. | International journal of STD & AIDS 19980901 |
| New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. | Journal of medicinal chemistry 19980827 |
| Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. | The Journal of infectious diseases 19980801 |
| Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. | The New England journal of medicine 19980730 |
| S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 19980601 |
| Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. | Journal of virology 19980501 |
| Novel HIV-protease inhibitors containing beta-hydroxyether and -thioether dipeptide isostere surrogates: modification of the P3 ligand. | Bioorganic & medicinal chemistry letters 19980421 |
| Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. | Bioorganic & medicinal chemistry letters 19980421 |
| Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. | Bioorganic & medicinal chemistry letters 19980317 |
| Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. | Proceedings of the National Academy of Sciences of the United States of America 19980203 |
| In vitro selection and characterization of VX-478 resistant HIV-1 variants. | Advances in experimental medicine and biology 19980101 |
| Nonsymmetrically substituted cyclic urea HIV protease inhibitors. | Journal of medicinal chemistry 19971205 |
| Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. | Journal of virology 19971101 |
| Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. | Antimicrobial agents and chemotherapy 19971101 |
| Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. | Antiviral research 19971101 |
| Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. | Biochemistry 19971007 |
| Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. | The Journal of antimicrobial chemotherapy 19970601 |
| In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. | The Journal of infectious diseases 19970501 |
| Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. | Antimicrobial agents and chemotherapy 19970501 |
| Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition. | Biochimica et biophysica acta 19970425 |
| A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. | Antimicrobial agents and chemotherapy 19970301 |
| Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. | Drug metabolism and disposition: the biological fate of chemicals 19970201 |
| Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV. | Journal of medicinal chemistry 19970117 |
| Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. | The Journal of biological chemistry 19961213 |
| The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. | Biochemical and biophysical research communications 19961204 |
| Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. | Journal of virology 19961201 |
| Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro. | Schweizerische medizinische Wochenschrift 19961026 |
| HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis. | Journal of medicinal chemistry 19961011 |
| Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation. | Journal of medicinal chemistry 19960816 |
| Paracyclophanes: a novel class of water-soluble inhibitors of HIV proteinase. | Journal of medicinal chemistry 19960816 |
| Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability. | Journal of medicinal chemistry 19960802 |
| Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design. | Journal of medicinal chemistry 19960705 |
| Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. | Antimicrobial agents and chemotherapy 19960601 |
| New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. | Antiviral research 19960501 |
| Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. | Proceedings of the National Academy of Sciences of the United States of America 19960220 |
| Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. | Antimicrobial agents and chemotherapy 19960201 |
| In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. | Antiviral research 19960101 |
| Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. | Antiviral research 19960101 |
| Design, synthesis, and resistance patterns of MP-134 and MP-167, two novel inhibitors of HIV type 1 protease. | AIDS research and human retroviruses 19960101 |
| In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. | Journal of virology 19950901 |
| Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. | Biochemistry 19950725 |
| Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. | AIDS research and human retroviruses 19950601 |
| Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase. | Journal of medicinal chemistry 19950512 |
| A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice. | Antiviral research 19950501 |
| Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. | Proceedings of the National Academy of Sciences of the United States of America 19950411 |
| In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. | Nature 19950406 |
| Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. | Journal of virology 19950401 |
| The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. | Antiviral research 19950301 |
| Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. | Antimicrobial agents and chemotherapy 19950201 |
| Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. | Virology 19950110 |
| Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. | The Journal of infectious diseases 19941201 |
| Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: heterocyclic ring systems containing P1' and P2' substituents. | Journal of medicinal chemistry 19941028 |
| Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. | Journal of medicinal chemistry 19940805 |
| Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323. | Antimicrobial agents and chemotherapy 19940701 |
| Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR. | Journal of medicinal chemistry 19940610 |
| The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors. | Journal of medicinal chemistry 19940415 |
| Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. | Journal of virology 19940301 |
| Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. | Antimicrobial agents and chemotherapy 19940201 |
| A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships. | Journal of medicinal chemistry 19931015 |
| In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. | Proceedings of the National Academy of Sciences of the United States of America 19930815 |
| Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. | Journal of medicinal chemistry 19930806 |
| Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. | Journal of medicinal chemistry 19930402 |
| 3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. | Journal of medicinal chemistry 19930122 |
| Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. | Antimicrobial agents and chemotherapy 19921201 |
| A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity. | Journal of medicinal chemistry 19920710 |
| Inhibitors of HIV-1 protease. | Journal of enzyme inhibition 19920101 |
| Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. | Antiviral research 19911201 |
| Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. | Journal of medicinal chemistry 19911101 |
| The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells. | Biochemical and biophysical research communications 19910415 |
| Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins. | Virology 19901101 |
| Rational design of peptide-based HIV proteinase inhibitors. | Science (New York, N.Y.) 19900420 |